<SEC-DOCUMENT>0001564590-19-039426.txt : 20191101
<SEC-HEADER>0001564590-19-039426.hdr.sgml : 20191101
<ACCEPTANCE-DATETIME>20191101161558
ACCESSION NUMBER:		0001564590-19-039426
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20191031
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20191101
DATE AS OF CHANGE:		20191101

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Orthofix Medical Inc.
		CENTRAL INDEX KEY:			0000884624
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19961
		FILM NUMBER:		191187025

	BUSINESS ADDRESS:	
		STREET 1:		3451 PLANO PARKWAY
		CITY:			LEWISVILLE
		STATE:			TX
		ZIP:			75056
		BUSINESS PHONE:		214-937-2000

	MAIL ADDRESS:	
		STREET 1:		3451 PLANO PARKWAY
		CITY:			LEWISVILLE
		STATE:			TX
		ZIP:			75056

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHOFIX INTERNATIONAL N V
		DATE OF NAME CHANGE:	19970708
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ofix-8k_20191031.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml  version="1.0" encoding="utf-8"?>
<!-- DFIN ActiveDisclosure(SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2019-11-01T17:54:55.7481851+00:00 -->
<!-- Version            : 5.0.0.208 -->
<!-- Package ID         : bf853a59a24d42f38fbab94c72f2ed83 -->
<!-- Copyright (c) 2019 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ofix="http://www.orthofix.com/20191031" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>
ofix-8k_20191031.htm
</title>
</head>
<!-- NG Converter v5.0.19273.161 -->
<body><div style="display:none">
	<ix:header>
		<ix:hidden>
			<ix:nonNumeric id="F_000001" name="dei:AmendmentFlag" contextRef="C_0000884624_20191031_20191031">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000004" name="dei:EntityCentralIndexKey" contextRef="C_0000884624_20191031_20191031">0000884624</ix:nonNumeric>
		</ix:hidden>
		<ix:references>
			<link:schemaRef xlink:type="simple" xlink:href="ofix-20191031.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef>
		</ix:references>
		<ix:resources>
			<xbrli:context id="C_0000884624_20191031_20191031">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000884624</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-10-31</xbrli:startDate>
					<xbrli:endDate>2019-10-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
		</ix:resources>
	</ix:header>
</div>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;border-top:Double 2.25pt;padding-top:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WASHINGTON, DC 20549 </p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM <ix:nonNumeric id="F_000000" name="dei:DocumentType" contextRef="C_0000884624_20191031_20191031">8-K</ix:nonNumeric></p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">CURRENT REPORT</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section 13 or 15(d) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of the Securities Exchange Act of 1934</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date of Report (Date of earliest event reported): <ix:nonNumeric id="F_000002" name="dei:DocumentPeriodEndDate" contextRef="C_0000884624_20191031_20191031" format="ixt:datemonthdayyearen">October 31, 2019</ix:nonNumeric></p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:24pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000003" name="dei:EntityRegistrantName" contextRef="C_0000884624_20191031_20191031">ORTHOFIX MEDICAL INC.</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of Registrant as specified in its charter)</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000007" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0000884624_20191031_20191031" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></p></td>
<td valign="bottom" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000006" name="dei:EntityFileNumber" contextRef="C_0000884624_20191031_20191031">0-19961</ix:nonNumeric></p></td>
<td valign="bottom" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000008" name="dei:EntityTaxIdentificationNumber" contextRef="C_0000884624_20191031_20191031">98-1340767</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="bottom" style="width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">of incorporation) </p></td>
<td valign="bottom" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">(Commission</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">File Number) </p></td>
<td valign="bottom" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">(IRS Employer </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Identification No.) </p></td>
</tr>
<tr>
<td valign="bottom" style="width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;">&#160;</p></td>
<td valign="bottom" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;">&#160;</p></td>
<td valign="bottom" style="width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;">&#160;</p></td>
<td valign="bottom" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;">&#160;</p></td>
<td valign="bottom" style="width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;">&#160;</p></td>
</tr>
<tr>
<td colspan="3" valign="bottom" style="width:66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000009" name="dei:EntityAddressAddressLine1" contextRef="C_0000884624_20191031_20191031">3451 Plano Parkway</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000010" name="dei:EntityAddressCityOrTown" contextRef="C_0000884624_20191031_20191031">Lewisville</ix:nonNumeric>, <ix:nonNumeric id="F_000011" name="dei:EntityAddressStateOrProvince" contextRef="C_0000884624_20191031_20191031" format="ixt-sec:stateprovnameen">Texas</ix:nonNumeric></p></td>
<td valign="bottom" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000012" name="dei:EntityAddressPostalZipCode" contextRef="C_0000884624_20191031_20191031">75056</ix:nonNumeric></p></td>
</tr>
<tr>
<td colspan="3" valign="bottom" style="width:66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices)</p></td>
<td valign="bottom" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric id="F_000013" name="dei:CityAreaCode" contextRef="C_0000884624_20191031_20191031">214</ix:nonNumeric>) <ix:nonNumeric id="F_000014" name="dei:LocalPhoneNumber" contextRef="C_0000884624_20191031_20191031">937-2000</ix:nonNumeric></p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" id="fis_financial_statements_and_exhibits">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<span style="font-style:italic;">see</span> General Instruction A.2. below):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000015" name="dei:WrittenCommunications" contextRef="C_0000884624_20191031_20191031" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:95.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td>
</tr>
<tr>
<td valign="top" style="width:4.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000016" name="dei:SolicitingMaterial" contextRef="C_0000884624_20191031_20191031" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:95.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td>
</tr>
<tr>
<td valign="top" style="width:4.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000017" name="dei:PreCommencementTenderOffer" contextRef="C_0000884624_20191031_20191031" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:95.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td>
</tr>
<tr>
<td valign="top" style="width:4.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000018" name="dei:PreCommencementIssuerTenderOffer" contextRef="C_0000884624_20191031_20191031" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:95.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8201;240.12b-2 of this chapter).</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company&#160;<span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000005" name="dei:EntityEmergingGrowthCompany" contextRef="C_0000884624_20191031_20191031" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section 12(b) of the Act:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:15%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Symbol(s)</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:45%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="top" style="width:38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000019" name="dei:Security12bTitle" contextRef="C_0000884624_20191031_20191031">Common stock, $0.10 par value per share</ix:nonNumeric></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:15%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000020" name="dei:TradingSymbol" contextRef="C_0000884624_20191031_20191031">OFIX</ix:nonNumeric></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:45%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000021" name="dei:SecurityExchangeName" contextRef="C_0000884624_20191031_20191031" format="ixt-sec:exchnameen">Nasdaq Global Select Market</ix:nonNumeric></p></td>
</tr>
</table></div>
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.33%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 5.02&#160;&#160;</span></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="text-decoration:underline;">Departure of Directors or Certain Officers&#59; Election of Directors&#59; Appointment of </span><span style="text-decoration:underline;">Certain Officers&#59; Compensatory Arrangements of Certain Officers</span><span style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CEO and Board Succession Matters</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 1, 2019, Jon Serbousek succeeded Bradley R. Mason as the President and Chief Executive Officer of Orthofix Medical Inc. (the &#8220;<span style="text-decoration:underline;">Company</span>&#8221;) in accordance with the Company&#8217;s previously announced succession plan. Consistent with such succession plan and the <span style="color:#000000;">Transition and Retirement Agreement entered into by the Company and Mr. Mason on February 25, 2019 (the &#8220;</span><span style="text-decoration:underline;color:#000000;">Transition and Retirement Agreement</span><span style="color:#000000;">&#8221;),</span> Mr. Mason (i) retired as an officer and director of the Company on October 31, 2019 and (i) commenced a 12-month period as a Company consultant beginning on November 1, 2019.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concurrently with Mr. Serbousek&#8217;s assumption of the office of President and Chief Executive Officer, the board of directors of the Company (the &#8220;<span style="text-decoration:underline;">Board</span>&#8221;) appointed Mr. Serbousek as a director to fill the Board seat vacated by Mr. Mason upon his retirement.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mr. Serbousek, age 59, has served since August 2019 as the Company&#8217;s President of Global Spine. Prior to joining the Company, he served since 2015 as an independent advisor to companies in the medical technology industry. During this period, Mr. Serbousek has also served as an independent board member of several privately-held companies in the medical technology industry.&#160;&#160;From 2008 until 2015, Mr. Serbousek served as a Senior Vice President of, and held senior operational positions with, Biomet, Inc. (&#8220;<span style="text-decoration:underline;">Biomet</span>&#8221;), a medical device company.&#160;&#160;From 2013 to 2015, he served as Worldwide President of Biomet Biologics, and prior thereto served as Worldwide Group President of Biomet Orthopedics from 2011 to 2013 and as President of U.S. Orthopedics from 2008 to 2011. From 2000 until 2008, Mr. Serbousek held diverse general management roles of increasing responsibility with the Spine and Biologics Divisions of Medtronic, Inc. (&#8220;<span style="text-decoration:underline;">Medtronic</span>&#8221;), a medical device company, including serving as Worldwide Division President, Spine and Vice President and General Manager, Worldwide Biologics.&#160;&#160;Before joining Medtronic, Mr. Serbousek served in various roles of increasing responsibility in the areas of joint reconstruction, spine, sports medicine, and biologics, at DePuy Orthopedics, a medical device company and subsidiary of Johnson &#38; Johnson, from 1987 to 2000, including as Vice President of Marketing and Product Development and Vice President of Spinal Operations.&#160;&#160;Mr. Serbousek earned a bachelor&#8217;s of science degree in Engineering from Washington State University, a master&#8217;s of science degree in Bioengineering from the University of Utah and later completed several advanced management programs including a program at the IMD International School of Management in Lausanne, Switzerland.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Mr.&#160;</span><span style="color:#000000;">Serbousek </span><span style="Background-color:#FFFFFF;">has no family relationship with any director or officer of the Company, or any person nominated or chosen by the Company to become a director or executive officer, and is not party to any related party transactions involving the Company.</span><span style="color:#000000;"> </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;color:#212529;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">As President and Chief Executive Officer, Mr. Serbousek will receive an annual base salary of $750,000 per year and a target bonus opportunity under the Company&#8217;s annual incentive plan of 100% of his then-current base salary. He will also be eligible to receive future, annual equity incentive awards (subject to approval of the Board or the Compensation Committee of the Board).</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change in Control and Severance Agreement and Indemnification Agreement with Mr. Serbousek</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 1, 2019, the Company and Mr. Serbousek entered into a Change in Control and Severance Agreement (the &#8220;<span style="text-decoration:underline;">Change in Control and Severance Agreement</span>&#8221;) that supersedes the prior change in control and severance agreement entered into by the Company and Mr. Serbousek when he originally joined the Company as its President of Global Spine.&#160;&#160;The Change in Control and Severance Agreement is materially consistent with the agreement that the Company had entered into with Mr. Mason in connection with his service as President and Chief Executive Officer.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Change in Control and Severance Agreement, Mr. Serbousek will be eligible to receive the following severance payments and benefits upon termination of the his employment (i) for death or &#8220;disability&#8221; (as defined in the agreement), (ii) by the Company without &#8220;cause&#8221; (as defined in the agreement) or (iii) by Mr. Serbousek for &#8220;good reason&#8221; (as defined in the agreement):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">Any unpaid base salary, accrued vacation or prior years&#8217; bonus payable or owing through the date of termination.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">The </span><span style="font-style:italic;font-family:Times New Roman;">pro rata</span><span style="font-family:Times New Roman;"> amount of any incentive compensation for the year of termination of employment (based on the number of days he is actually employed by the Company during the year in which termination of employment occurs) based on the achievement of the Company's performance goals for such year.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">An amount equivalent to 1.5 times the sum of: (i) Mr. Serbousek&#8217;s annual base salary plus (ii) his current year&#8217;s target bonus&#59; provided that during the 24-month period following any change in control, the foregoing amount increases to 2.0 times such sum.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-family:Times New Roman;">If Mr. Serbousek timely elects to continue coverage under the Consolidated Omnibus Budget Reconciliation Action of 1985 (&#8220;</span><span style="text-decoration:underline;font-family:Times New Roman;">COBRA</span><span style="font-family:Times New Roman;">&#8221;) and remains eligible to receive COBRA coverage, the Company will reimburse him for his monthly pre</span><span style="font-family:Times New Roman;">mium payments for health care coverage under COBRA for a period of 18 months.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">$18,750 for use towards outplacement services (plus an additional $6,250 during the 24-month period following any change in control).</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The right to receive cash payments following a change in control remains subject to a &#8220;double trigger&#8221; provision, such that payments by the Company are only owed if Mr. Serbousek separates from employment in specific circumstances in connection with or following a change in control.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The agreement contains restrictive covenants, including non-competition and non-solicitation covenants effective so long as Mr. Serbousek is an employee and for a period of 18 months after his employment is terminated.&#160;&#160;The agreement also contains provisions that define certain vesting and exercise rights in connection with time-based stock options, time-based restricted stock and time-based restricted stock units granted (such as by defining the terms &#8220;cause,&#8221; &#8220;good reason,&#8221; and &#8220;qualified retirement&#8221; for purposes of all prior and subsequent time-based equity grants).&#160;&#160;The agreement does not guarantee any minimum levels of cash or equity-based compensation levels during Mr. Serbousek&#8217;s employment with the Company.&#160;&#160;The term of the agreement continues in effect until the earlier of (i) the parties&#8217; satisfaction of their respective obligations or (ii) the execution of a written agreement between the Company and Mr. Serbousek terminating the agreement.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consulting Agreement with Mr. Mason</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As contemplated by the Transition and Retirement Agreement, the Company and Mr. Mason have entered into a Consulting Agreement, dated November 1, 2019 (the &#8220;<span style="text-decoration:underline;">Consulting Agreement</span>&#8221;).&#160;&#160;The Consulting Agreement provides that Mr. Mason will provide ongoing transition assistance to the Company through October 31, 2020, for a fee of $40,000 per month.&#160;&#160;Such consulting services will be provided upon request by, and as directed by, Mr. Serbousek, provided that Mr. Mason will not be required to provide more than 50 hours of service in any month.&#160;&#160;Under the terms of the Consulting Agreement, Mr. Mason has agreed that the non-competition and non-solicitation obligations contained in his change in control and severance agreement with the Company shall continue during the 12-month consulting period and for an additional 18 months thereafter.&#160;&#160;In the event that the Company terminates the Consulting Agreement without cause prior to October 31, 2020, Mr. Mason will remain entitled to receive his monthly consulting fee through such date.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7.01.</p></td>
<td valign="top" style="background-color:#FFFFFF;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Regulation FD Disclosure</span>.</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:4pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 1, 2019, the Company issued a press release regarding the succession matters described above. That press release is furnished herewith as Exhibit 99.1.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:9pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information included in this Current Report on Form 8-K under this Item&#160;7.01 (including Exhibit&#160;99.1) shall not be deemed &#8220;filed&#8221; for the purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 9.01.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:underline;Background-color:#FFFFFF;">Financial Statements and Exhibits.</span></p></td></tr></table></div>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</p></td>
<td valign="top" style="width:95%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#252525;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibits</p></td>
</tr>
<tr>
<td valign="top" style="width:5%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top" style="width:95%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="ofix-ex101_34.htm"><span style="text-decoration:underline;">Change in Control and Severance Agreement, dated November 1, 2019, between Orthofix Medical Inc. and Jon Serbousek.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:5%;">
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#252525;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="top" style="width:95%;">
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="ofix-ex102_35.htm"><span style="text-decoration:underline;">Consulting Agreement, dated November 1, 2019, between Orthofix Medical Inc. and Bradley R. Mason.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:5%;">
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#252525;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="top" style="width:95%;">
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="ofix-ex991_7.htm"><span style="text-decoration:underline;">Press release, dated November 1, 2019.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:5%;">
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td valign="top" style="width:95%;">
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES </span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. <span style="margin-left:36pt;"></span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div style="align:right;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:231.35pt;;">
<tr>
<td style="width:24.2pt;"></td>
<td style="width:24.2pt;"></td>
<td style="width:181.95pt;"></td>
<td style="width:1pt;"></td>
</tr>
<tr>
<td colspan="3" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Orthofix Medical Inc.</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;text-align:left;">&#160;</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;text-align:left;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By: </p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;text-align:left;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;text-align:left;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">/s/ Kimberley A. Elting</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;text-align:left;">&#160;</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;text-align:left;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;text-align:left;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kimberley A. Elting </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Legal and Administrative Officer</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;text-align:left;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: <span style="Background-color:#FFFFFF;color:#000000;">November 1, 2019</span></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ofix-ex101_34.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
ofix-ex101_34.htm
</title>
</head>
<!-- NG Converter v5.0.19273.161 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Exhibit 10.1</font></p>
<p style="text-align:center;margin-top:0pt;line-height:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">CONSULTING AGREEMENT</font></p>
<p style="text-align:justify;margin-top:24pt;line-height:12pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Consulting Agreement (the &#8220;<font style="text-decoration:underline;">Agreement</font>&#8221;), effective as of November 1, 2019 (the &#8220;<font style="text-decoration:underline;">Effective Date</font>&#8221;), is entered into by and between Orthofix Medical Inc. (&#8220;<font style="text-decoration:underline;">Orthofix</font>&#8221;), a Delaware corporation having its principal offices at 3451 Plano Parkway, Lewisville, Texas 75056, and Bradley R. Mason (&#8220;<font style="text-decoration:underline;">Mr.</font> <font style="text-decoration:underline;">Mason</font>&#8221;).</p>
<p style="text-align:justify;margin-top:13pt;line-height:12pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, Mr. Mason has determined to retire from the position of President and Chief Executive Officer of Orthofix as of October 31, 2019 (the &#8220;<font style="text-decoration:underline;">Termination Date</font>&#8221;);</p>
<p style="text-align:justify;margin-top:12pt;line-height:12pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, Orthofix and Mr. Mason previously entered into that certain Transition and Retirement Agreement, dated as of February 25, 2019 (the &#8220;<font style="text-decoration:underline;">Retirement Agreement</font>&#8221;);</p>
<p style="text-align:justify;margin-top:12pt;line-height:12pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, Mr. Mason, in his former capacity as Orthofix&#8217;s President and Chief Executive Officer, has certain background information and historical knowledge of ongoing operations matters and issues affecting Orthofix&#8217;s business and related interests;</p>
<p style="text-align:justify;margin-top:12pt;line-height:12pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, Orthofix desires to engage Mr. Mason to provide limited consulting services in order to provide continued access to such background information and historical knowledge;</p>
<p style="text-align:justify;margin-top:12pt;line-height:12pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, Mr. Mason is willing and able to provide such consulting services to Orthofix according to the terms and conditions set forth herein; and</p>
<p style="text-align:justify;margin-top:12pt;line-height:12pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, the parties have come to an agreement regarding Mr. Mason&#8217;s retirement and his provision of consulting services.</p>
<p style="text-align:justify;margin-top:12pt;line-height:12pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Orthofix and Mr. Mason agree as follows:</p>
<p style="margin-top:11pt;line-height:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="margin-left:36pt;">TERMINATION OF EMPLOYMENT</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1</font></p></td>
<td valign="top">
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">General</font>. The parties agree that Mr. Mason&#8217;s last day of employment with Orthofix (including any of its subsidiaries and affiliates) will be the Termination Date. As of the Termination Date, Mr. Mason will resign all of the offices, directorships, appointments, and other positions he holds with Orthofix and all of its parents, subsidiaries, and affiliates. After the Termination Date, Mr. Mason shall not represent that he is an employee or other representative of Orthofix for any purpose. As of the Termination Date, Mr. Mason shall not be eligible to participate in, or be covered by, any employee benefit plan or program offered by or through Orthofix and shall not receive any benefits or payments from Orthofix, except as otherwise provided in the Retirement Agreement, under the terms of applicable benefits plans, or by applicable law.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.2</font></p></td>
<td valign="top">
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Separation Payments and Benefits</font>. The parties agree that the Retirement Agreement sets forth those payments and benefits to which Mr. Mason is entitled as of his Termination Date.&nbsp;&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.3</font></p></td>
<td valign="top">
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="text-decoration:underline;">Restrictive Covenants</font>. Mr. Mason hereby reaffirms and agrees to comply with the restrictive covenants set forth in Section 9 of the Change in Control and Severance Agreement entered into as of November 1, 2016 (the &#8220;<font style="text-decoration:underline;">Severance Agreement</font>&#8221;) (including Non-Disparagement, Cooperation, Non-Disclosure, Innovations, Non-Solicitation, and Non-Competition); provided, that, notwithstanding anything to the contrary in Sections 9(e) and 9(f) of the Severance Agreement, Mr. Mason hereby agrees that the non-solicitation and non-competition restrictive </p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">covenants shall apply during the Consulting Term (as defined below) and for a period of eighteen (18) months following the end</font><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of the Consulting Term.</font></p></td></tr></table></div>
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.<font style="margin-left:36pt;">CONSULTING SERVICES</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.1</font></p></td>
<td valign="top">
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">General</font>. Mr. Mason agrees to provide to Orthofix consulting services as further <font style="letter-spacing:-0.15pt;">described in </font><font style="text-decoration:underline;letter-spacing:-0.15pt;">Exhibit A</font><font style="letter-spacing:-0.15pt;"> (&#8220;</font><font style="text-decoration:underline;letter-spacing:-0.15pt;">Consulting Services</font><font style="letter-spacing:-0.15pt;">&#8221;) (a) upon request by Orthofix&#8217;s President and Chief Executive Officer in accordance with the terms and conditions of this Agreement (but in no event more than fifty (50) hours per month during the Consulting Term) and (b) as directed by Orthofix&#8217;s President and Chief Executive Officer. Mr. Mason shall perform the Consulting Services in accordance with the standard of care, loyalty, and diligence normally observed in his profession, shall devote his best efforts, skills, and energies to the performance of such Consulting Services, and shall at all times perform the Consulting Services and conduct his business and affairs in accordance with all applicable federal, state, and local laws and regulations. Orthofix may, in its sole discretion, engage any third party or parties to provide services to Orthofix or any Orthofix subsidiary or </font><font style="letter-spacing:0.15pt;">affiliate that are the same, similar, or different from the Consulting Services, without </font>obligation or liability therefore or in connection therewith to Mr. Mason.&nbsp;&nbsp;It is the intention of the parties that the Consulting Services will be limited to those services that do not cause or require Mr. Mason to receive internal financial reports or metrics.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.2</font></p></td>
<td valign="top">
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Compensation</font>. As compensation for Mr. Mason&#8217;s performance of the Consulting <font style="letter-spacing:-0.15pt;">Services and as consideration for the extension of the non-solicitation and non-competition provisions as set forth in </font><font style="text-decoration:underline;letter-spacing:-0.15pt;">Section 1.3</font><font style="letter-spacing:-0.15pt;">, Mr. Mason shall receive the compensation expressly set forth in </font><font style="text-decoration:underline;letter-spacing:-0.15pt;">Exhibit B</font><font style="letter-spacing:-0.15pt;"> (&#8220;</font><font style="text-decoration:underline;letter-spacing:-0.15pt;">Compensation</font><font style="letter-spacing:-0.15pt;">&#8221;). The Compensation shall be the sole compensation and value to which Mr. Mason is entitled in consideration for any performance or provision of Consulting Services under this Agreement and for the extension of the non-solicitation and non-competition provisions as set forth in </font><font style="text-decoration:underline;letter-spacing:-0.15pt;">Section 1.3</font><font style="letter-spacing:-0.15pt;">.</font><font style="text-decoration:underline;letter-spacing:-0.15pt;"> </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.3</font></p></td>
<td valign="top">
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Term and Termination</font>.<font style="text-decoration:underline;"> </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Term of Agreement</font>. This Agreement shall commence on the Effective Date and, unless earlier terminated in accordance with the terms of this Agreement, shall continue in effect until the first anniversary of the Effective Date (the &#8220;<font style="text-decoration:underline;">Expiration Date</font>&#8221;), at which time it will automatically terminate. The term of this Agreement shall be referred to as the &#8220;<font style="text-decoration:underline;">Consulting</font> <font style="text-decoration:underline;">Term</font>.&#8221;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Termination Without Cause</font>. This Agreement may be terminated prior to the Expiration Date by either party in its sole discretion, with or without cause, by providing the other party with thirty (30) days&#8217; advance written notice of termination. In the event that this Agreement is terminated by the Company without Cause prior to the Expiration Date, Mr. Mason shall be entitled to receive the Compensation due pursuant to <font style="text-decoration:underline;">Section 2.2</font> of this Agreement for the period between the effective date of such termination and the Expiration Date.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Termination for Breach</font>. Either party may terminate this Agreement prior to the Expiration Date by giving written notification to the other party if such other party materially breaches this Agreement. Such termination of this Agreement will take effect if, after ten (10) days of such written notification, such breach is not cured.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="text-decoration:underline;">Consequences of Termination or Expiration</font>. Upon the termination or expiration of this Agreement for any reason, Mr. Mason shall remain entitled to the Compensation due </p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;">Page </font>2</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pursuant to </font><font style="text-decoration:underline;">Section 2.2</font><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of this Agreement in respect of the services provided through the effective date of such termination or expiration, but, except as provided in </font><font style="text-decoration:underline;">Section </font><font style="text-decoration:underline;">2.3(b)</font><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, Mr. Mason shall not be entitled to any further compensation or consideration from Orthofix or its subsidiaries or affiliates in respect of any services, activities, or performance after the effective date of such termination or expiration. In addit</font><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ion, upon termination of this Agreement by Orthofix prior to April 1, 2020 for any reason other than pursuant to </font><font style="text-decoration:underline;">Section 2.3(c)</font><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, Mr. Mason shall be considered to be in compliance with the terms of this Agreement for purposes of Section 3(e) of the Retireme</font><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nt Agreement and shall continue to receive the Compensation he would have received had the Agreement not been terminated.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Survival</font>. The obligations contained in <font style="text-decoration:underline;">Sections 1.3, 2.3(b), 2.3(d), 2.5, 4, 5, 6, and 7</font> of this Agreement and this <font style="text-decoration:underline;">Section 2.3(e)</font> shall survive the expiration or termination of this Agreement.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;color:#000000;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.4</font></p></td>
<td valign="top">
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;color:#000000;letter-spacing:-0.1pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Independent Contractor Status</font>. The relationship of Mr. Mason to Orthofix in performing <font style="letter-spacing:-0.15pt;">the Consulting Services shall be that of an independent contractor, and nothing contained in this Agreement shall create or imply a partnership, joint venture, agency, or employment relationship between Mr. Mason and Orthofix. Mr. Mason shall have sole control of the manner and means of performing the Consulting Services under this Agreement and shall complete such services in accordance with Consultant&#8217;s own means and methods of </font>work. Consultant is not authorized to bind Orthofix or to otherwise make any representation, agreement, or commitment on behalf of Orthofix. Mr. Mason agrees that he shall not claim or represent to be an employee, partner, agent, or principal of Orthofix.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.5</font></p></td>
<td valign="top">
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Taxes</font>. Mr. Mason is solely responsible for paying, when due, any and all taxes, including, but not limited to, income and estimated taxes, incurred as a result of the compensation and expenses paid by Orthofix to Mr. Mason for Consulting Services.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.6</font></p></td>
<td valign="top">
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Nonexclusivity</font>. Mr. Mason is a former Orthofix employee and, as such, is bound by obligations that existed before the execution of this Agreement (e.g., those contained in the Severance Agreement, the Retirement Agreement and the Indemnification Agreement, dated August 1, 2018 (collectively, the &#8220;<font style="text-decoration:underline;">Prior Agreements</font>&#8221;)). This Agreement in no way amends, modifies, or supersedes such ongoing obligations, except as expressly provided herein.</p></td></tr></table></div>
<p style="margin-top:13pt;line-height:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.<font style="margin-left:36pt;"></font>WARRANTIES AND REPRESENTATIONS</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</font></p></td>
<td valign="top">
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Performance</font>. Mr. Mason represents and warrants that he has the qualifications and skills necessary to perform the Consulting Services and shall perform such Consulting Services in accordance with the terms, provisions, and conditions of this Agreement and in a competent, diligent, and professional manner.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2</font></p></td>
<td valign="top">
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Authority</font>. Mr. Mason represents and warrants having the full right and authority to enter into and perform under this Agreement.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.3</font></p></td>
<td valign="top">
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">No Conflict</font>. Mr. Mason represents and warrants that entering into and performing under <font style="letter-spacing:-0.1pt;">this Agreement does not and shall not breach, violate, or conflict with any provision of any Court order, decree, judgment, agreement, or understanding, oral or written, to which Mr. Mason is a party or by which Mr. Mason is bound, including, without limitation, any non-competition, exclusivity, or similar agreement or covenant of Mr. Mason or any obligations or restrictions of Mr. Mason under any contract or agreement.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;">Page </font>3</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.4</font></p></td>
<td valign="top">
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="text-decoration:underline;">Nondisclosure</font><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Mr. Mason represents and warrants that he has not disclosed and will </font><font style="letter-spacing:-0.1pt;">not disclose to Orthofix or any of its employees or contractors any confidential, proprietary, or</font><font style="letter-spacing:-0.1pt;"> secret information of any third party to whom or regarding which Mr. Mason is under a duty of confidentiality.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.5</font></p></td>
<td valign="top">
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Material Breach</font>. Any breach of the warranties, representations, and other agreements set forth in this <font style="text-decoration:underline;">Section 3</font> shall be deemed to be a material breach of this Agreement.</p></td></tr></table></div>
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.<font style="margin-left:36pt;"></font>INDEMNIFICATION; LIABILITY</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</font></p></td>
<td valign="top">
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">By Mr. Mason</font>. Mr. Mason shall indemnify, defend, and hold Orthofix and its <font style="letter-spacing:-0.05pt;">subsidiaries, and affiliates and each of their officers, directors, employees, agents, and shareholders free and harmless from any and all claims, demands, losses, suits, judgments, penalties, and liabilities of any kind and nature whatsoever (including, without limitation, reasonable attorney&#8217;s fees and costs, through the appellate process, if any) arising in any way out of (i) a breach by Mr. Mason of this Agreement or the representations and warranties contained in </font><font style="text-decoration:underline;letter-spacing:-0.05pt;">Section 3</font><font style="letter-spacing:-0.05pt;">, or (ii) the negligence or willful misconduct of Mr. Mason.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</font></p></td>
<td valign="top">
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Limitation of Liability</font>. SUBJECT IN ANY CASE TO SUCH LIMITATION OR EXCLUSION OF LIABILITY BEING LAWFUL, AND NOTWITHSTANDING ANYTHING TO THE CONTRARY IN THIS AGREEMENT, ORTHOFIX SHALL NOT BE LIABLE TO MR. MASON, OR ANY PERSON CLAIMING THROUGH MR. MASON, BY REASON OF ANY REPRESENTATION, IMPLIED WARRANTY, COVENANT, CONDITION, OR OTHER TERM OR ANY DUTY AT COMMON LAW OR UNDER ANY STATUTE, OR UNDER THE EXPRESS TERMS OF THIS AGREEMENT, FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, EXEMPLARY, SPECIAL, LIQUIDATED, OR PUNITIVE LOSS OR DAMAGE (WHETHER FOR LOSS OF PROFIT OR OTHERWISE AND WHETHER OCCASIONED BY THE NEGLIGENCE OF ORTHOFIX OR ITS SUBSIDIARIES OR AFFILIATES AND EACH OF THEIR EMPLOYEES OR AGENTS OR OTHERWISE) ARISING OUT OF OR IN CONNECTION WITH ANY ACT OR OMISSION OF ORTHOFIX.</p></td></tr></table></div>
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.<font style="margin-left:36pt;">PROPRIETARY RIGHTS</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.1</font></p></td>
<td valign="top">
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Ownership of Orthofix Property</font>. As used herein, the term &#8220;<font style="text-decoration:underline;">Orthofix Property</font>&#8221; means, <font style="letter-spacing:-0.1pt;">collectively and individually, any and all discoveries, inventions, processes, improvements, technology, devices, products, works, derivative works, information, ideas, concepts, and other intellectual property of any kind created, made, discovered, belonging to, held, or acquired by Orthofix and/or any Orthofix subsidiary or affiliate at any time, and any and all Intellectual Property Rights therein and related thereto. As used herein, the term &#8220;</font><font style="text-decoration:underline;letter-spacing:-0.1pt;">Intellectual Property Rights</font><font style="letter-spacing:-0.1pt;">&#8221; means, collectively and individually, any and all patents, patent applications, copyrights, trademarks, trade names, trade secrets, and other intellectual property rights of any kind, and any and all registrations and applications therefore, whether in the United States and/or anywhere else. Orthofix and/or any Orthofix subsidiary or affiliate shall retain any and all rights, title, and interest in and to any and all Orthofix Property, whether existing now or coming into existence or becoming Orthofix Property at any time in the future. Neither Orthofix nor any Orthofix subsidiary or affiliate transfers, conveys, assigns, or grants to Mr. Mason or any third party, and nothing in this Agreement or its performance shall be construed to constitute any transfer, conveyance, assignment, or grant to Mr. Mason or any third party of, any right, title, interest, license, grant, expectation, or entitlement in or to any Orthofix Property, or any other property or Intellectual Property Rights of any kind created, made, discovered, belonging to, held, or acquired by Orthofix or any Orthofix subsidiary or affiliate.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;">Page </font>4</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.2</font></p></td>
<td valign="top">
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="text-decoration:underline;">Ownership of Inventions</font><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. As used herein, the term &#8220;</font><font style="text-decoration:underline;">Inventions and Works</font><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; means any </font><font style="letter-spacing:-0.15pt;">and all processes, products, procedures, systems, discoveries, designs, configurations, technology, works of authorship (including, but not limited to, computer programs), trade secrets, and impro</font><font style="letter-spacing:-0.15pt;">vements which Mr. Mason develops, discovers, authors, makes, conceives, reduces to practice, or otherwise acquires during the Consulting Term (either solely or jointly with others) and which are related to any or all of the products and/or business of Orth</font><font style="letter-spacing:-0.15pt;">ofix. Any and all Inventions and Works, and any and all Intellectual Property Rights therein and related thereto, shall be owned solely and exclusively by Orthofix and shall be held by Mr. Mason only for the sole benefit of Orthofix. Orthofix shall own all</font><font style="letter-spacing:-0.15pt;"> of the exclusive rights to such works of authorship under all copyright law, all international copyright conventions and treaties, and all similar laws in the United States and any other place and jurisdiction. Mr. Mason hereby agrees to assign, transfer,</font><font style="letter-spacing:-0.15pt;"> and convey, and hereby assigns, transfers, and conveys, to Orthofix all Invention and Works </font><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and any and all Intellectual Property Rights therein and related thereto, whether in the United States and/or elsewhere.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.3</font></p></td>
<td valign="top">
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Nondisclosure</font>. Mr. Mason shall not, during the Consulting Term or at any time after the termination or expiration of this Agreement, provide to others or use for Mr. Mason&#8217;s own benefit or for the benefit of another any information relating to any and all Inventions and Works, any and all Orthofix Property, and/or any and all products, services, customers and business operations and activities of Orthofix and/or any Orthofix subsidiary or affiliate (collectively, &#8220;<font style="text-decoration:underline;">Proprietary Information</font>&#8221;), except that Mr. Mason may use Proprietary Information during the Consulting Term to the extent necessary for Mr. Mason to perform his obligations hereunder. Mr. Mason shall not disclose, during the Consulting Term or at any time after the termination or expiration of this Agreement, any Proprietary Information, except if and to the extent expressly authorized by Orthofix in advance, or if and to the extent such Proprietary Information is available to the general public when such Proprietary Information is provided to Mr. Mason or becomes available thereafter by Orthofix.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.4</font></p></td>
<td valign="top">
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Further Assurances</font>. Upon Orthofix&#8217;s request, Mr. Mason agrees to provide any assistance, including, without limitation, providing any information and documents, executing any documents and affidavits, providing any testimony, and/or rendering any other assistance, as is necessary or useful for Orthofix to secure, perfect, and obtain sole and exclusive ownership to any and all Inventions and Works, and all Intellectual Property Rights therein and related thereto, or to otherwise fully effect and implement the provisions in this <font style="text-decoration:underline;">Section 5</font>.<font style="text-decoration:underline;"> </font></p></td></tr></table></div>
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.<font style="margin-left:36pt;"></font>EQUITABLE RELIEF</p>
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mr. Mason acknowledges that any breach of this Agreement by Mr. Mason may give rise to irreparable injury to Orthofix, which may not be adequately compensated by damages or, if such injury to Orthofix may be adequately compensated by damages, such damages are difficult or impossible to calculate. Accordingly, in the event of a breach or threatened breach of this Agreement by Mr. Mason, Orthofix shall have, in addition to any remedies it may have at law, the right to an injunction or other equitable relief, whether temporary, interlocutory, or final, to prevent the violation of its rights hereunder without further demonstration of such injury, without any obligation or requirement by Orthofix to post any bond or security. Orthofix will be entitled to recover attorneys&#8217; fees and costs incurred by it in any proceedings for such equitable relief in which it prevails.</p>
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.<font style="margin-left:-283pt;"></font>GENERAL PROVISIONS</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.1</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_AEIOULastRenderedPageBreakAEIOU6"></a><font style="text-decoration:underline;">Notices</font>. Notices, invoices, communications, and payments shall be submitted to the offices identified below. Contractual notices and communications hereunder shall be deemed made as of </p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;">Page </font>5</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the date of delivery, if given by overnight courier service. Notices sent by r</font><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">egistered or certified mail, postage prepaid, and addressed to the party to receive such notice of communication at the address given below, or such other address as may hereafter be designated by notice in writing, shall be deemed communicated as of the d</font><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ay of receipt or the fifth day after mailing, whichever occurs first.</font></p></td></tr></table></div>
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;margin-left:15.38%;text-indent:0%;color:#000000;letter-spacing:-0.05pt;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If to Orthofix:</p>
<p style="margin-top:12pt;line-height:12pt;margin-bottom:0pt;margin-left:23.08%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Orthofix Medical Inc.</p>
<p style="margin-top:0pt;line-height:12pt;margin-bottom:0pt;margin-left:23.08%;text-indent:0%;color:#000000;letter-spacing:0.05pt;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attn: Chief Legal and Administrative Officer</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:23.08%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3451 Plano Parkway</p>
<p style="margin-top:0pt;line-height:12pt;margin-bottom:0pt;margin-left:23.08%;text-indent:0%;color:#000000;letter-spacing:0.05pt;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lewisville, Texas 75056</p>
<p style="margin-bottom:12pt;margin-top:12pt;line-height:12pt;margin-left:15.38%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If to Mr. Mason, address on file with Orthofix.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.2</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Assignment</font>. Neither this Agreement nor any rights hereunder may be assigned and no duties or obligations under this Agreement may be delegated by Mr. Mason without the prior written consent of Orthofix, which Orthofix may give or deny or condition in its sole discretion. Orthofix may assign this Agreement or any or all of the rights hereunder and/or delegate any duties or obligations hereunder without the consent of Mr. Mason, including, without limitation, to any Orthofix subsidiary or affiliate or to a purchaser of or successor, whether by merger, corporate reorganization, or asset purchase, regarding all or part of Orthofix or any Orthofix subsidiary or affiliate or the assets, business, and properties of Orthofix or any Orthofix subsidiary or affiliate. Subject to the foregoing, this Agreement shall be binding on the heirs, executors, administrators, successors, and assigns of the respective parties.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.3</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Waiver</font>. No waiver, alteration, or modification of any of the provisions of this Agreement shall be binding unless it is in writing and signed by a duly authorized representative of each party.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.4</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Amendment</font>. This Agreement or any of its terms, provisions, or conditions may be <font style="letter-spacing:-0.05pt;">extended, renewed, varied, modified, or otherwise amended at any time only by a writing signed by a duly authorized representative of Orthofix and Mr. Mason. Any permitted assignment, delegation, or transfer under </font><font style="text-decoration:underline;letter-spacing:-0.05pt;">Section 7.2</font><font style="letter-spacing:-0.05pt;"> of this Agreement shall be deemed not to constitute an amendment if and to the extent such assignment, delegation, or transfer does not result in or cause any amendment, supplement, variation, modification, change, or alteration of or addition to any term, condition, provision, warranty, representation, or covenant of this Agreement, other than the identity of the party and third party involved in such assignment, delegation, or transfer.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.5</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Severability</font>. If any provision of this Agreement is for any reason declared to be invalid or <font style="letter-spacing:-0.15pt;">unenforceable, the validity and enforce ability of the remaining provisions shall not be affected thereby. Such invalid or unenforceable provision shall be deemed modified to the extent necessary to render it valid and enforceable, and if no modification shall render it valid and enforceable, this Agreement shall be construed as if not containing such provision and the rights and obligations of the parties shall be construed and enforced accordingly.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.6</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Counterparts</font>. This Agreement may be executed in two or more counterparts, by facsimile or in writing, which shall together constitute one and the same agreement.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.7</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_AEIOULastRenderedPageBreakAEIOU7"></a><font style="text-decoration:underline;">Attorneys&#8217; Fees</font>. In the event that any party to this Agreement shall commence any suit or action to interpret or enforce this Agreement, including an action for declaratory relief, the prevailing party in such action, shall recover that party&#8217;s costs and expenses incurred in connection with the </p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;">Page </font>6</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">suit or action, including attorneys&#8217; fees and costs of appeal, if any, whi</font><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ch may be set by the Court in the same action or in a separate action brought for that purpose, in addition to any other relief to which that party may be entitled</font><font style="font-weight:bold;">.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.8</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Compliance with Law</font>. Mr. Mason shall perform all obligations and carry out any activities under or in connection with this Agreement at his own cost and expense (except solely as expressly provided otherwise in <font style="text-decoration:underline;">Exhibit B</font> to this Agreement) in accordance with Orthofix policies and all applicable laws, including, but not limited to, any laws regarding fraud and abuse, false claims, anti-kickback, medical device promotion, unfair competition, data privacy, insider trading, consumer protection, and requirements to obtain approvals, consents, licenses, registrations, payment of taxes, customs fees or duties, or other fees or charges.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.9</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Entire Agreement</font>. This Agreement, including its exhibits, supersedes any and all other <font style="letter-spacing:-0.1pt;">agreements, either oral or in writing, between the parties hereto with respect to the subject matter hereof, and no other agreement, statement, or promise relating to the subject matter of this Agreement which is not contained herein shall be valid or binding. Notwithstanding the foregoing, the parties agree that the Prior Agreements shall not be superseded by this Agreement (except as expressly amended hereby) and confirm that the Prior Agreements, unless separately terminated in accordance with their terms, remain in full force and effect and are intended to be adjuncts to this Agreement.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;letter-spacing:-0.05pt;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;letter-spacing:-0.05pt;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.10</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;letter-spacing:-0.05pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Governing Law</font>. The validity, interpretation, performance, and enforcement of this Agreement shall be governed by, and interpreted in accordance with, the federal laws of the United States of America and the laws of the state of Texas without regard to conflict-of-laws principles that may require the application of the laws of any other jurisdiction. Each party acknowledges and agrees that all disputes which arise in connection with, or are related to this Agreement, or any breach thereof, shall be resolved, if not settled, by litigation only in Collin County, Texas or the federal court otherwise having territorial jurisdiction over such county and subject matter jurisdiction over the dispute, and not elsewhere. To this end, Mr. Mason waives any rights he may have to insist that litigation to which he is a party be had in any other venue and covenants not to sue Orthofix in any court other than the above-referenced court.</p></td></tr></table></div>
<p style="text-align:center;margin-bottom:268pt;margin-top:25pt;line-height:12pt;text-indent:0%;color:#000000;letter-spacing:1.3pt;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">***</p>
<p style="margin-bottom:268pt;margin-top:25pt;line-height:12pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;">Page </font>7</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:0pt;line-height:12pt;margin-bottom:0pt;margin-left:0.77%;margin-right:1.5%;text-indent:8.46%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU8"></a><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, the Parties hereto have executed this Agreement as of the 28th day of October, 2019.</font></p>
<p style="margin-top:0pt;line-height:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;line-height:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;line-height:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100.91%;">
<tr>
<td style="width:46.1%;"></td>
<td style="width:13.46%;"></td>
<td style="width:41.35%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:0pt;line-height:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;letter-spacing:-0.15pt;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ORTHOFIX MEDICAL INC.</p></td>
<td valign="top" >
<p style="margin-top:0pt;line-height:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;line-height:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;letter-spacing:-0.15pt;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MR. MASON:</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;line-height:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;line-height:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;line-height:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;letter-spacing:-0.15pt;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Kimberley A. Elting</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;line-height:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;line-height:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;line-height:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;line-height:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;letter-spacing:-0.15pt;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Bradley R. Mason</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="margin-top:0pt;line-height:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;letter-spacing:-0.15pt;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kimberley A. Elting</p></td>
<td valign="top" >
<p style="margin-top:0pt;line-height:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="margin-top:0pt;line-height:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;letter-spacing:-0.15pt;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bradley R. Mason</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:0pt;line-height:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;letter-spacing:-0.15pt;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Legal and Administrative Officer</p></td>
<td valign="top" >
<p style="margin-top:0pt;line-height:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;line-height:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:0pt;line-height:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:1pt;line-height:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;">Page </font>8</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:1pt;line-height:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU9"></a><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;line-height:12pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">EXHIBIT B</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;line-height:12pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Consulting Services</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;line-height:12pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;line-height:12pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Mr. Mason shall timely provide the services deemed necessary by Orthofix&#8217;s President and Chief Executive Officer related to the transition of Mr. Mason&#8217;s former duties and responsibilities.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;line-height:12pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;line-height:12pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Mr. Mason shall provide the Consulting Services remotely and shall not have any access to Orthofix premises, personnel, equipment, or other property during the Consulting Term unless otherwise directed by Orthofix&#8217;s President and Chief Executive Officer.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;line-height:12pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;line-height:12pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">During the Consulting Term, Mr. Mason will report to Orthofix&#8217;s President and Chief Executive Officer.&nbsp;&nbsp;Mr. Mason agrees to accept requests for services and work assignments from the President and Chief Executive Officer.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;line-height:12pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;line-height:12pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Mr. Mason will not be expected to, and will not, provide more than fifty (50) hours of Consulting Services per month during the Consulting Term.</p></td></tr></table></div>
<p style="text-align:center;margin-top:13pt;line-height:12pt;margin-bottom:0pt;margin-left:2.31%;text-indent:0%;color:#000000;letter-spacing:1.3pt;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">***</p>
<p style="margin-top:12pt; clear:both;margin-bottom:0pt;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;">Page </font>9</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU10"></a><font style="text-decoration:underline;">EXHIBIT B</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Compensation</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:97.86%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Mr. Mason shall be eligible to receive a flat fee of $40,000.00 per month, plus reimbursement of reasonable expenses incurred at the direction of the President and Chief Executive Officer.</p></td>
<td valign="top" style="width:2.14%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="margin-bottom:255pt;line-height:25pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:1pt;line-height:9pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;">Page </font>10</a></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>ofix-ex102_35.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
ofix-ex102_35.htm
</title>
</head>
<!-- NG Converter v5.0.19273.161 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Exhibit 10.2</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ORTHOFIX MEDICAL INC.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><font style="text-decoration:underline;">CHANGE IN CONTROL AND SEVERANCE AGREEMENT</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This AGREEMENT (the &#8220;<font style="text-decoration:underline;">Agreement</font>&#8221;) is made and entered into as of November 1, 2019 (the &#8220;<font style="text-decoration:underline;">Effective Date</font>&#8221;), by and between Orthofix Medical Inc., a Delaware corporation (together with its direct and indirect subsidiaries, the &#8220;<font style="text-decoration:underline;">Company</font>&#8221;), and Jon Serbousek (the &#8220;<font style="text-decoration:underline;">Executive</font>&#8221;).</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;"><font style="text-decoration:underline;">RECITALS</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, the Executive is expected to make significant contributions to the profitability, growth and financial strength of the Company;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, the Company believes that it is important to provide the Executive with severance benefits upon certain terminations of employment to provide the Executive with enhanced financial security and incentive and encouragement to remain with the Company; </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, the Company recognizes that the possibility of a Change in Control (as hereinafter defined) and the uncertainty that it would cause could result in the departure or distraction of the Executive, to the detriment of the Company and its stockholders; </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, the Company desires to encourage the continued employment of the Executive by the Company and wants assurance that it shall have the continued dedication, loyalty and service of, and the availability of objective advice and counsel from, the Executive notwithstanding the possibility, threat or occurrence of a Change in Control; and</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, the Company and Executive are parties to a Change in Control and Severance Agreement, dated August 5, 2019 (the &#8220;<font style="text-decoration:underline;">Prior CiC Agreement</font>&#8221;), and the parties desire that this Agreement shall constitute a novation of such Prior CiC Agreement, such that, effective upon execution and delivery of this Agreement, the Prior CiC Agreement shall be deemed null and void.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOW, THEREFORE, in consideration of the mutual covenants and promises contained herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Definitions</font>.&nbsp;&nbsp;As used in this Agreement, the following terms have the following meanings which are equally applicable to both the singular and plural forms of the terms defined:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="color:#000000;">&#8220;</font><font style="text-decoration:underline;color:#000000;">2012 LTIP</font><font style="color:#000000;">&#8221; shall mean the Company&#8217;s 2012 Long-Term Incentive Plan, as amended from time-to-time (including after the Effective Date).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Board</font>&#8221; shall mean the <font style="color:#000000;">Board of Directors of the Company.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>(c)<font style="margin-left:36pt;"></font><font style="color:#000000;">&#8220;</font><font style="text-decoration:underline;color:#000000;">Cause</font><font style="color:#000000;">&#8221; shall mean (i) willful and intentional commission by the Executive of one or more material acts of (A) fraud, misappropriation or embezzlement related </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in Control and Severance Agreement&#8212;<font style="font-size:12pt;font-family:Times New Roman;"> </font>Jon Serbousek</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective Date:&nbsp;&nbsp;November 1, 2019<font style="margin-left:36pt;">Page </font>1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;"></font>&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;">to the business or property of the Company or (B) moral turpitude; (ii) conviction for, </font><font style="color:#000000;">or guilty plea to, or plea of nolo contendere to, a felony; or (iii) fraud or willful misconduct committed by the Executive that caused or otherwise materially contributed to the requirement for an accounting restatement of the Company&#8217;s financial statemen</font><font style="color:#000000;">ts due to noncompliance with any financial reporting requirement (other than a restatement due to a change in accounting rules).</font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> No act or omission shall be deemed willful, intentional or material for purposes of this definition if taken or omitted to be t</font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">aken by Executive in a good faith belief that such act or omission to act was in the best interests of the Company or if done at the express direction of the </font><font style="color:#000000;">Board </font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or the board of directors or principal executive officer of any acquirer of the Company.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font> &#8220;<font style="text-decoration:underline;">Change in Control</font>&#8221; shall mean the occurrence of any of the following events:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;"></font>the acquisition by any individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Exchange Act) of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act), in any individual transaction or series of related transactions, of 50% or more of either (A) the then outstanding shares of common stock of Parent (the &#8220;<font style="text-decoration:underline;">Outstanding Common Stock</font>&#8221;) or (B) the combined voting power of the then outstanding voting securities of Parent entitled to vote generally in the election of directors (the &#8220;<font style="text-decoration:underline;">Outstanding Voting Securities</font>&#8221;); <font style="text-decoration:underline;">excluding</font>, <font style="text-decoration:underline;">however</font>, the following:&nbsp;&nbsp;(1) any acquisition directly from Parent, other than an acquisition by virtue of the exercise of a conversion privilege unless the security being so converted was itself acquired directly from Parent; (2) any acquisition by Parent; (3) any acquisition by any employee benefit plan (or related trust) sponsored or maintained by Parent or any entity controlled by Parent; or (4)&#160;any acquisition pursuant to a transaction which complies with clauses (A), (B) and (C) of subsection (iii) of this definition of Change in Control;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)<font style="margin-left:36pt;"></font>a change in the composition of the Board such that the individuals who as of the Effective Date constitute the Board (the &#8220;<font style="text-decoration:underline;">Incumbent Board</font>&#8221;) cease for any reason to constitute at least a majority of the Board; <font style="text-decoration:underline;">provided</font>, <font style="text-decoration:underline;">however</font>, for purposes of this paragraph, that any individual who becomes a member of the Board subsequent to the Effective Date, whose appointment, election, or nomination for election by Parent&#8217;s shareholders was approved by a vote of at least a majority<font style="font-weight:bold;"> </font>of those individuals who are members of the Board and who were also members of the Incumbent Board (or deemed to be such pursuant to this proviso) shall be considered as though such individual were a member of the Incumbent Board; but <font style="text-decoration:underline;">provided</font> <font style="text-decoration:underline;">further</font> that any such individual whose initial assumption of office occurs as a result of either an actual or threatened election contest (as such terms are used in Rule 14a-11 of Regulation 14A promulgated under the Exchange Act) or other actual or threatened solicitation of proxies or consents by or on behalf of a Person other than the Board shall not be so considered as a member of the Incumbent Board;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a>(iii)<font style="margin-left:36pt;"></font>consummation of a reorganization, merger, consolidation or other business combination or the sale or other disposition of all or substantially all of the assets of Parent (including assets that are shares held by Parent in its subsidiaries) (any such transaction, a &#8220;<font style="text-decoration:underline;">Business Combination</font>&#8221;); <font style="text-decoration:underline;">expressly excluding</font>, <font style="text-decoration:underline;">however</font>, any such Business Combination </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in Control and Severance Agreement&#8212;Jon Serbousek</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective Date:&nbsp;&nbsp;November 1, 2019<font style="margin-left:36pt;">Page </font>2</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;"></font>&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pursuant to which all of the following conditions are met:&nbsp;&nbsp;(A)&#160;all or substantially all of the Person(s) who are the </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">beneficial owners of the Outstanding Common Stock and Outstanding Voting Securities, respectively, immediately prior to such Business Combination will beneficially own, directly or indirectly, more than 50% of, respectively, the outstanding shares of commo</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n stock, and the combined voting power of the outstanding voting securities entitled to vote generally in the election of directors, as the case may be, of the entity resulting from such Business Combination (including, without limitation, an entity which </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as a result of such transaction owns Parent or all or substantially all of Parent&#8217;s assets either directly or through one or more subsidiaries) in substantially the same proportions as their ownership, immediately prior to such Business Combination, of the</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Outstanding Common Stock and Outstanding Voting Securities, as the case may be, (B)&#160;no Person (other than Parent, any employee benefit plan (or related trust) of Parent or such entity resulting from such Business Combination) will beneficially own, direct</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ly or indirectly, 50% or more of, respectively, the outstanding shares of common stock of the entity resulting from such Business Combination or the combined voting power of the outstanding voting securities of such entity entitled to vote generally in the</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> election of directors except to the extent that such ownership existed prior to the Business Combination, and (C)&#160;individuals who were members of the Incumbent Board will constitute at least a majority of the members of the board of directors of the entit</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">y resulting from such Business Combination;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iv)<font style="margin-left:36pt;"></font>the approval by the shareholders of Parent of a complete liquidation or dissolution of Parent;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(v)<font style="margin-left:36pt;"></font>the Company shall sell or dispose of, in a single transaction or series of related transactions, business operations that generated two-thirds of the consolidated revenues of the Company (determined on the basis of Company&#8217;s four most recently completed fiscal quarters for which reports have been filed under the Exchange Act) and such disposal shall not be exempted pursuant to clause (iii) of this definition of Change in Control; </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a>(vi)<font style="margin-left:36pt;"></font>Parent files a report or proxy statement with the Securities and Exchange Commission pursuant to the Exchange Act disclosing in response to Form 8-K or Schedule 14A (or any successor schedule, form or report or item therein) that a change in control of Parent has or may have occurred or will or may occur in the future pursuant to any then-existing agreement or transaction; notwithstanding the foregoing, unless determined in a specific case by a majority vote of the Board, a &#8220;<font style="text-decoration:underline;">Change in Control</font>&#8221; shall not be deemed to have occurred solely because:&nbsp;&nbsp;(A) an entity in which Parent directly or indirectly beneficially owns 50% or more of the voting securities, or any Parent-sponsored employee stock ownership plan, or any other employee plan of the Company, either files or becomes obligated to file a report or a proxy statement under or in response to Schedule 13D, Schedule 14D-1, Form 8-K or Schedule 14A (or any successor schedule, form or report or item therein) under the Exchange Act, disclosing beneficial ownership by form or report or item therein, disclosing beneficial ownership by it of shares of stock of Parent, or because Parent reports that a change in control of Parent has or may have occurred or will or may occur in the future by reason of such beneficial ownership or (B) any Company&#8209;sponsored employee stock ownership plan, or any other employee plan of the Company, either files or becomes obligated to file a report or a proxy statement under or in response to Schedule 13D, Schedule 14D-1, Form 8-K or Schedule 14A (or </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in Control and Severance Agreement&#8212;Jon Serbousek</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective Date:&nbsp;&nbsp;November 1, 2019<font style="margin-left:36pt;">Page </font>3</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;"></font>&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any successor schedule, form or report or item therein) under the Exchange Act, disclosing beneficial ownership by form or report or item therein, disclosing beneficial ownership by </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">it of shares of stock of Parent, or because Parent reports that a change in control of Parent has or may have occurred or will or may occur in the future by reason of such beneficial ownership; or</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(vii)<font style="margin-left:36pt;"></font>any other transaction or series of related transactions occur that have substantially the effect of the transactions specified in any of the preceding clauses in this definition.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding this definition of &#8220;<font style="text-decoration:underline;">Change in Control</font>,&#8221; the Board, in its sole discretion, may determine that a Change in Control has occurred for purposes of this Agreement, even if the events giving rise to such Change in Control are not expressly described in the above definition.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:36pt;"></font><font style="color:#000000;">&#8220;</font><font style="text-decoration:underline;color:#000000;">CiC Date</font><font style="color:#000000;">&#8221; shall mean the date on which a Change in Control occurs.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">CiC Period</font>&#8221; shall mean the twenty four (24)-month period commencing on the CiC Date; provided, however, if the Company terminates the Executive&#8217;s employment with the Company prior to the CiC Date but on or after a Potential CiC Date, and it is reasonably demonstrated that the Executive&#8217;s (i) employment was terminated at the request of an unaffiliated third party who has taken steps reasonably calculated to effect a Change in Control or (ii)&#160;termination of employment otherwise arose in connection with or in anticipation of the Change in Control, then the &#8220;<font style="text-decoration:underline;">CiC Period</font>&#8221; shall mean the twenty four (24)-month period beginning on the date immediately prior to the date of the Executive&#8217;s termination of employment with the Company.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a>(g)<font style="margin-left:36pt;"></font> &#8220;<font style="text-decoration:underline;">CiC Period Good Reason</font>&#8221; shall mean the occurrence of any of the following without the written consent of the Executive: (i) a requirement that the Executive work principally from a location that is more than thirty (30) miles from his or her current principal place of employment, (ii) any reduction in the Executive&#8217;s Total Compensation, (iii) any material breach of this Agreement or any other material agreement with the Executive by the Company or any successor entity, or (iv) any diminution in the Executive&#8217;s employment position, authority, duties, responsibilities or line of reporting structure, or the assignment to the Executive of any duties materially inconsistent with the Executive&#8217;s position and title immediately prior to consummation of the Change in Control (including, for example, if the Executive was the Chief Financial Officer of the Company immediately prior to consummation of a Change in Control and is not the Chief Financial Officer of the Company immediately following consummation of the Change in Control, then a diminution in the Executive&#8217;s responsibilities will have occurred), in each case excluding for this purpose an isolated, insubstantial and inadvertent action taken in good faith and which is promptly remedied by employer.&nbsp;&nbsp;The Executive shall only have CiC Period Good Reason if (A) the Executive has provided notice of termination to the Company of any of the foregoing conditions within ninety (90) days of the initial existence of the condition, (B) the Company does not cure such condition within thirty (30) days following receipt of such notice of termination, and (C) if such condition is not cured within such thirty (30) day period, the Executive actually terminates employment within sixty (60) days after the notice of termination.&nbsp;&nbsp;The Executive&#8217;s mental or physical incapacity following the occurrence of an event </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in Control and Severance Agreement&#8212;Jon Serbousek</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective Date:&nbsp;&nbsp;November 1, 2019<font style="margin-left:36pt;">Page </font>4</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;"></font>&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">described above in clauses (i), (ii), (iii) or (iv) shall not affect the Executive&#8217;s ability to terminate employment for CiC Period Good Reason, and the Executive&#8217;s death following </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">delivery</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of a notice of termination for CiC Period Good Reason sha</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ll not affect the Executive&#8217;s estate&#8217;s entitlement to the severance benefits provided hereunder upon a termination of employment for CiC Period Good Reason.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(h)<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Compensation Committee</font>&#8221; shall mean the Compensation Committee of the Board. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;"></font> &#8220;<font style="text-decoration:underline;">Disability</font>&#8221; as used in this Agreement shall have the meaning given that term by any disability insurance the Company carries at the time of termination that would apply to the Executive. Otherwise, the term &#8220;<font style="text-decoration:underline;">Disability</font>&#8221; shall mean the inability of the Executive to perform each of the essential duties of the Executive&#8217;s position by reason of a medically determinable physical or mental impairment which is potentially permanent in character or which can be expected to last for a continuous period of not less than twelve (12) months. Any dispute as to whether or not the Executive has a &#8220;<font style="text-decoration:underline;">Disability</font>&#8221; for purposes of this Agreement shall be resolved by a physician reasonably satisfactory to the Board and the Executive (or his legal representative, if applicable). If the Board and the Executive (or his legal representative, if applicable) are unable to agree on a physician, then each shall select one physician and those two physicians shall pick a third physician and the determination of such third physician shall be binding on the parties.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(j)<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Exchange Act</font>&#8221; shall mean the Securities Exchange Act of 1934, as amended.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(k)<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Good Reason</font>&#8221; shall mean: (i) during a CiC Period, CiC Period Good Reason; and (ii) during a Non-CiC Period, Non-CiC Period Good Reason. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(l)<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Non-CiC Period</font>&#8221; shall mean any period of time that is not a CiC Period. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU6"></a>(m)<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Non-CiC Period Good Reason</font>&#8221; shall mean the occurrence of any of the following without the written consent of the Executive: (i) a requirement that the Executive work principally from a location that is more than fifty (50) miles from his or her current principal place of employment, (ii) any 10% or greater reduction in the sum of the Executive&#8217;s base salary and target bonus opportunity, (iii) any 20% or greater reduction in the grant date fair value of equity-based compensation annually awarded to the Executive (other than reductions that are made substantially <font style="font-style:italic;">pro rata</font> to other executives of the Company), or (iv) any material breach of this Agreement or any other material agreement with the Executive by the Company or any successor entity. The Executive shall only have Non-CiC Period Good Reason if (A) the Executive has provided notice of termination to the Company of any of the foregoing conditions within ninety (90) days of the initial existence of the condition, (B) the Company does not cure such condition within thirty (30) days following receipt of such notice of termination, and (C) if such condition is not cured within such thirty (30) day period, the Executive actually terminates employment within sixty (60) days after the notice of termination.&nbsp;&nbsp;The Executive&#8217;s mental or physical incapacity following the occurrence of an event described above in clauses (i), (ii), (iii), </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in Control and Severance Agreement&#8212;Jon Serbousek</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective Date:&nbsp;&nbsp;November 1, 2019<font style="margin-left:36pt;">Page </font>5</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;"></font>&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iv), or (v) shall not affect the Executive&#8217;s ability to terminate employment for Non-CiC Pe</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">riod Good Reason, and the Executive&#8217;s death following </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">delivery</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of a notice of termination for Non-CiC Period Good Reason shall not affect the Executive&#8217;s estate&#8217;s entitlement to the severance benefits provided hereunder upon a termination of employment for</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Non-CiC Period Good Reason.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(n)<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Parent</font>&#8221; shall mean Orthofix Medical Inc. and its successors.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(o)<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Person</font>&#8221; shall include individuals or entities such as corporations, partnerships, companies, firms, business organizations or enterprises, and governmental or quasi-governmental bodies. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(p)<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Potential CiC Date</font>&#8221; shall mean the earliest to occur of: (i) the date on which Parent executes an agreement or letter of intent, the consummation of the transactions described in which would result in the occurrence of a Change in Control or (ii) the date on which the Board approves a transaction or series of transactions, the consummation of which would result in a Change in Control; provided, however, that such date shall become null and void when, in the opinion of the Board, Parent or the respective third party has abandoned or terminated such transaction or series of transactions without consummation. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(q)<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Qualified Retirement</font>&#8221; shall mean a retirement from Service by the Executive in which, at the time of such retirement, the sum of the Executive&#8217;s age and aggregate 12-month completed periods of Service (whether or not such completed 12-month periods are consecutive), in each case without giving credit for any partial years, equals or exceeds 75.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(r)<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Service</font>&#8221; shall have the meaning ascribed to such term in the 2012 LTIP.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(s)<font style="margin-left:36pt;"></font>&#8220;<font style="text-decoration:underline;">Total Compensation</font>&#8221; shall mean aggregate of base salary, target bonus opportunity, employee benefits (retirement plan, welfare plans, and fringe benefits), and grant date fair value of equity-based compensation, but excluding for the avoidance of doubt any reductions caused by the failure to achieve performance targets) taken as a whole.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Term of Agreement</font>.&nbsp;&nbsp;The term of this Agreement (the &#8220;<font style="text-decoration:underline;">Term</font>&#8221;) shall commence on the Effective Date and shall continue in effect until the earlier of (i) the parties&#8217; satisfaction of their respective obligations under this Agreement or (ii) the execution of a written agreement between the Company and the Executive terminating this Agreement. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU7"></a>3.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Certain Terminations of Employment During a Non-CiC Period</font>.&nbsp;&nbsp;If, during a Non-CiC Period, the Executive&#8217;s employment with the Company terminates as a result of death, the Executive terminates his or her employment as a result of Disability or for Non-CiC Period Good Reason, or the Company terminates the Executive&#8217;s employment without Cause, the Company shall pay or provide to the Executive (i) the Executive&#8217;s annual base salary due through the Executive&#8217;s date of termination, (ii) any amounts or benefits owing to the Executive as of the Executive&#8217;s date of termination under the then applicable benefit plans of the Company, at the time such amounts or benefits are due (including any accrued vacation payable), (iii) any amounts owing to the Executive for reimbursement of expenses properly incurred by the </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in Control and Severance Agreement&#8212;Jon Serbousek</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective Date:&nbsp;&nbsp;November 1, 2019<font style="margin-left:36pt;">Page </font>6</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;"></font>&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Executive prior to the Executive&#8217;s date of termination, wh</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ich shall be subject to and paid in accordance with the Company&#8217;s expense reimbursement policy, (iv) if, for the calendar year prior to the Executive&#8217;s termination, Executive has achieved performance goals such that Executive has earned a bonus under any a</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nnual cash incentive program of the Company (an &#8220;</font><font style="text-decoration:underline;">Annual Cash Incentive Program</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;) and such Annual Cash Incentive Program bonus with respect to such prior calendar year has not yet been determined and/or paid, the amount of such bonus, payable at the same ti</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">me as payments are made to other participants under such Annual Cash Incentive Program, and (v) a </font><font style="font-style:italic;">pro rata</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> amount of any Annual Cash Incentive Program bonus, if any, with respect to the year of termination (based on the number of days the Executive was emp</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">loyed by the Company during such year of termination) based on the achievement of applicable performance goals for such year, payable during the following year at the same time as payments are made to other participants under such Annual Cash Incentive Pro</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">gram (collectively, the &#8220;</font><font style="text-decoration:underline;">Accrued Amounts</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;).&nbsp;&nbsp;Subject to the Executive&#8217;s compliance with the restrictive covenants in Section 9 hereof and the Executive&#8217;s execution and non-revocation of the release described in Section 5 hereof, the Company shall also pay </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the Executive, in a cash lump sum within ten (10) days following the Release Effective Date (as defined below), an amount equal to one and one-half (1.5) times the sum of (A) the Executive&#8217;s annual base salary in effect as of the Executive&#8217;s date of ter</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mination (without giving effect to any reduction of base salary that has occurred within the 12-month period preceding such date of termination), (B) the Executive&#8217;s current annual target cash bonus amount under the Annual Cash Incentive Program (without g</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iving effect to any reduction of such annual target amount that has occurred within the 12-month period preceding such date of termination and (C) $12,500 to be used by the Executive for outplacement services (such sum, the &#8220;</font><font style="text-decoration:underline;">Severance Amount</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;).</font><font style="font-weight:bold;">&nbsp;&nbsp;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithsta</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nding the foregoing, if the Severance Amount could be paid to the Executive during the subsequent taxable year of the Executive rather than the Executive&#8217;s taxable year in which the Executive&#8217;s date of termination occurs based on when the Executive execute</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s and delivers the release described in Section 5 hereof to the Company, then, to the extent that the Severance Amount constitutes nonqualified deferred compensation subject to Section 409A of Internal Revenue Code of 1986, as amended (the &#8220;</font><font style="text-decoration:underline;">Code</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;), the Sev</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">erance Amount shall not be paid earlier than the first business day of the later of such taxable years.&nbsp;&nbsp;In addition, subject to the Executive&#8217;s compliance with the restrictive covenants in Section 9 hereof and the Executive&#8217;s execution and non-revocation </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of the release described in Section 5 hereof, the Company shall reimburse the Executive on a monthly basis for the Executive&#8217;s monthly premium payments for health care coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985 (&#8220;</font><font style="text-decoration:underline;">COBRA</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;) for </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Executive and the Executive&#8217;s eligible dependents for a period of eighteen (18) months, provided that the Executive and, if applicable, the Executive&#8217;s eligible dependents are currently enrolled in the applicable plan(s) of the Company at the time of t</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">he Executive&#8217;s termination and that the Executive timely elects to continue the Executive&#8217;s coverage under COBRA; provided, however, that the Company&#8217;s obligation to reimburse the Executive for such premiums shall cease on the date the Executive is no long</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">er eligible to receive COBRA coverage.&nbsp;&nbsp;The Executive must advise the Company as soon as the Executive becomes eligible for health care coverage from a third party (e.g., spouse&#8217;s employer, the Executive&#8217;s subsequent employer, or any other party with a rel</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ationship with the Executive).</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in Control and Severance Agreement&#8212;Jon Serbousek</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective Date:&nbsp;&nbsp;November 1, 2019<font style="margin-left:36pt;">Page </font>7</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;"></font>&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU8"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Termination of Employment During a CiC Period</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;If, during a CiC Period, the Executive&#8217;s employment with the Company terminates as a result of death, the Executive terminates his or her employment as a result of Disability or</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for CiC Period Good Reason, or the Company terminates the Executive&#8217;s employment without Cause, the Company shall: (A)&#160;pay or provide to the Executive the Accrued Amounts, and (B) subject to the Executive&#8217;s compliance with the restrictive covenants in Sec</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tion 9 hereof and the Executive&#8217;s execution and non-revocation of the release described in Section 5 hereof, (i) pay to the Executive, in a cash lump sum within ten (10) days following the Release Effective Date, an amount equal to two (2) times the sum of</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (A) the Executive&#8217;s annual base salary in effect as of the Executive&#8217;s date of termination (without giving effect to any reduction of base salary that has occurred within the 12-month period preceding such date of termination), (B) the Executive&#8217;s current</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> annual target cash bonus amount under the Annual Cash Incentive Program (without giving effect to any reduction of such annual target amount that has occurred within the 12-month period preceding such date of termination and (C) $12,500 to be used by the </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Executive for outplacement services (such sum, the &#8220;</font><font style="text-decoration:underline;">CiC Severance Amount</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;); provided, however, that if the CiC Severance Amount could be paid to the Executive during the subsequent taxable year of the Executive rather than the Executive&#8217;s taxable year in w</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">hich the Executive&#8217;s date of termination occurs based on when the Executive executes and delivers the release described in Section 5 hereof to the Company, then, to the extent that the CiC Severance Amount constitutes nonqualified deferred compensation sub</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ject to Section 409A of the Code, the CiC Severance Amount shall not be paid earlier than the first business day of the later of such taxable years; and (ii) reimburse the Executive on a monthly basis for the Executive&#8217;s monthly premium payments for health</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> care coverage under COBRA for the Executive and the Executive&#8217;s eligible dependents for a period of eighteen (18) months, provided that the Executive and, if applicable, the Executive&#8217;s eligible dependents are currently enrolled in the applicable plan(s) </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of the Company at the time of the Executive&#8217;s termination and that the Executive timely elects to continue the Executive&#8217;s coverage under COBRA; provided, however, that the Company&#8217;s obligation to reimburse the Executive for such premiums shall cease on th</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e date the Executive is no longer eligible to receive COBRA coverage.&nbsp;&nbsp;The Executive must advise the Company as soon as the Executive becomes eligible for health care coverage from a third party (e.g., spouse&#8217;s employer, the Executive&#8217;s subsequent employer</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, or any other party with a relationship with the Executive).&nbsp;&nbsp; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU9"></a>5.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Payments Contingent Upon Release Agreement</font>.&nbsp;&nbsp;As a condition to receiving the Severance Amount or the CiC Severance Amount, as applicable, and the reimbursement of COBRA premiums pursuant to Sections 3 or 4 hereof, the Executive will execute a release of claims substantially in the form of the release attached hereto as <font style="text-decoration:underline;">Exhibit A</font> (the &#8220;<font style="text-decoration:underline;">Release</font>&#8221;).&nbsp;&nbsp;Within ten (10) business days of the Executive&#8217;s date of termination, the Company shall deliver to the Executive the Release for the Executive to execute.&nbsp;&nbsp;The Executive will forfeit all rights to receive the Severance Amount or the CiC Severance Amount, as applicable, and the reimbursement of COBRA premiums pursuant to Sections 3 or 4 hereof unless, within forty-five (45) days of delivery of the Release by the Company to the Executive, the Executive executes and delivers the Release to the Company and such Release has become irrevocable by virtue of the expiration of the revocation period specified therein without the Release having been revoked (the first such date, the &#8220;<font style="text-decoration:underline;">Release Effective Date</font>&#8221;).&nbsp;&nbsp;The Company&#8217;s obligation to pay the Severance Amount or the CiC Severance Amount, as applicable, or to reimburse COBRA </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in Control and Severance Agreement&#8212;Jon Serbousek</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective Date:&nbsp;&nbsp;November 1, 2019<font style="margin-left:36pt;">Page </font>8</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;"></font>&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">premiums pursuant to Sections 3 or 4 h</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ereof, is subject to the occurrence of the Release Effective Date, and if the Release Effective Date does not occur, then the Company shall have no obligation to make such payments or reimbursements.&nbsp;&nbsp;Any reimbursements of COBRA premiums pursuant to Sectio</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ns 3 or 4 hereof that would otherwise have become due prior to the Release Effective Date shall be paid in a cash lump sum within ten (10) days following the Release Effective Date; provided, that if any reimbursements of COBRA premiums pursuant to Section</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s 3 or 4 hereof could be paid to the Executive during a different taxable year of the Executive than the Executive&#8217;s taxable year in which the Executive&#8217;s date of termination occurs based on when the Executive executes and delivers the Release to the Compa</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ny, then, to the extent that the reimbursements constitute nonqualified deferred compensation subject to Section 409A of the Code, the reimbursement amounts shall not be paid earlier than the first business day of the later of such taxable years.&nbsp;&nbsp;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the e</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">vent the Executive breaches one or more of the restrictive covenants set forth in Section 9 hereof, the Executive shall forfeit the Executive&#8217;s right to receive the Severance Amount or the CiC Severance Amount, as applicable, and the reimbursement of COBRA</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> premiums pursuant to Sections 3 or 4 hereof, and, to the extent such amounts have been paid to the Executive, shall repay to the Company the after-tax amount of any such previously paid amounts.</font><font style="font-size:10.5pt;font-family:Arial;">&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Time-Based Stock Options, Time-Based Restricted Stock, and Time-Based Restricted Stock Unit Vesting and Exercisability</font>.&nbsp;&nbsp;The provisions set forth in Sections 6(a), (b), (c) and (e) below shall apply with respect to (a) all time-based vesting stock options of the Company (&#8220;<font style="text-decoration:underline;">Time-Based Stock Options</font>&#8221; or &#8220;<font style="text-decoration:underline;">Options</font>&#8221;) granted to the Executive before or after the date of this Agreement, (b) all time-based vesting shares of restricted stock of the Company (&#8220;<font style="text-decoration:underline;">Time-Based Restricted Stock</font>&#8221; or &#8220;<font style="text-decoration:underline;">TBRS</font>&#8221;) granted to the Executive before or after the date of this Agreement, and (c) all time-based vesting restricted stock units of the Company (&#8220;<font style="text-decoration:underline;">Time-Based RSU</font>&#8221; or &#8220;<font style="text-decoration:underline;">TBRSU</font>&#8221;) granted to the Executive before or after the date of this Agreement.&nbsp;&nbsp;Such provisions shall supersede and override any conflicting provisions set forth in applicable award agreements of the Company governing applicable grants, and shall be incorporated by reference into the terms of such award agreements. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU10"></a>(a)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Termination with or without Cause; Certain Voluntary Terminations</font>. If, prior to vesting, the Executive&#8217;s Service is terminated for any reason other than (i) death, (ii) Disability, (iii) a Qualified Retirement occurring no less than six (6) months after the grant date of the Option (the &#8220;<font style="text-decoration:underline;">Grant Date</font>&#8221;) or (iv) a circumstance providing for accelerated vesting pursuant Section 6(d) hereof, the unvested portion of the applicable Option, TBRS, or TBRSU shall be cancelled and revert back to the Company as of the date of such termination of Service, and the Executive shall have no further right or interest therein unless the Compensation Committee in its sole discretion shall determine otherwise.&nbsp;&nbsp;In such event, the Executive shall have the right, subject to the other terms and conditions set forth in this Agreement and the applicable plan, to exercise such Option, to the extent it has vested as of the date of such termination of Service, at any time within three (3) months after the date of such termination of Service, subject to the earlier expiration of the Option on the ten (10)-year anniversary of grant or such other term as is provided in the applicable equity award agreement otherwise governing such grant (the &#8220;<font style="text-decoration:underline;">Expiration Date</font>&#8221;).&nbsp;&nbsp;To the extent the vested portion of the Option is not exercised within such three (3)-month period, such Option shall be cancelled and revert back to </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in Control and Severance Agreement&#8212;Jon Serbousek</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective Date:&nbsp;&nbsp;November 1, 2019<font style="margin-left:36pt;">Page </font>9</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;"></font>&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Company, and the Executive or any permitted transferee pursuant to the terms of the applicable award agreement, as applicable, shall have no further right or interest therein.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Termination of Service for Death or Disability</font>. If the Executive&#8217;s Service terminates by reason of death or Disability, as of the date of such termination of Service (i) the unvested portion of any Option shall automatically vest and become immediately exercisable in full and (ii) any TBRS and any TBRSU shall automatically vest in full.&#160;&#160;The full portion of any unexercised Option shall remain exercisable by the Executive (or any person entitled to do so) at any time within eighteen (18) months after the date of such termination of Service, subject to the earlier expiration of such Option on the Expiration Date. To the extent such Option is not exercised within such&nbsp;&nbsp;period, such Option shall be cancelled and revert back to the Company, and the Executive or any permitted transferee pursuant to the terms of the applicable award agreement, as applicable, shall have no further right or interest therein.&nbsp;&nbsp;The shares subject to any such TBRSU shall be delivered no later than sixty (60) days following such termination of Service.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Termination of Service for Certain Qualified Retirements</font>. If the Executive&#8217;s Service terminates by reason of a Qualified Retirement occurring no less than six (6) months after the Grant Date but prior to the second anniversary of the Grant Date, any Option shall automatically vest and become immediately exercisable, and any TBRS and any TBRSU shall be considered vested, as of the date of such termination of Service, with respect to the aggregate number of shares of common stock of Parent as to which such Option, TBRS, or TBRSU, as applicable, would have been vested as of such second anniversary of the Grant Date.&nbsp;&nbsp;If the Executive&#8217;s Service terminates by reason of a Qualified Retirement after the second anniversary of the Grant Date but before the third anniversary of the Grant Date, any Option shall automatically vest and become immediately exercisable, and any TBRS and any TBRSU shall be considered vested, as of the date of such termination of Service, with respect to the aggregate number of shares of common stock of Parent as to which such Option, TBRS, or TBRSU, as applicable, would have been vested as of such third anniversary of the Grant Date.&nbsp;&nbsp;If the Executive&#8217;s Service is terminated by reason of a Qualified Retirement after the third anniversary of the Grant Date but before the fourth anniversary of the Grant Date, any Option shall automatically vest and become immediately exercisable, and any TBRS and any TBRSU shall be considered vested, in full as of the date of such termination of Service.&nbsp;&nbsp;In each of the circumstances described in the preceding three sentences, (i) the applicable Option shall remain exercisable by the Executive (or any person entitled to do so) at any time within eighteen (18) months after the date of such termination of Service, subject to the earlier expiration of the Option on the Expiration Date, and to the extent such Option is not exercised within such eighteen (18)-month period, the Option shall be cancelled and revert back to the Company, and the Executive or any permitted transferee pursuant to the terms of the applicable award agreement, as applicable, shall have no further right or interest therein, and (ii) the shares subject to any such TBRSU shall be delivered no later than sixty (60) days following such termination of Service.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU11"></a>(d)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Certain Additional Change in Control Circumstances</font>. In the event that any Option is assumed or continued, or substituted for new common stock options or another equity-</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in Control and Severance Agreement&#8212;Jon Serbousek</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective Date:&nbsp;&nbsp;November 1, 2019<font style="margin-left:36pt;">Page </font>10</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;"></font>&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">based award of a successor entity, or parent or subsidiary thereof (with appropriate adjustments as to the n</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">umber of shares and option exercise prices), or any unvested portion of the TBRS or the TBRSU is assumed or continued, or substituted for new restricted common stock, new restricted stock unit, or another equity-based award of a successor entity, or parent</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or subsidiary thereof (with appropriate adjustments as to the number of shares), in each case upon the consummation of any Change in Control, and the employment of the Executive with the Company is terminated by the Company without Cause or by the Executi</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ve for CiC Period Good Reason, in each case during a CiC Period, (i) such Option shall be fully vested and may be exercised in full, to the extent applicable, beginning on the date of such termination and for the twenty four (24)-month period immediately f</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ollowing such termination (subject to the earlier expiration of the Option on the Expiration Date) or for such longer period as the Compensation Committee shall determine and (ii) the unvested portion of such TBRS and such TBRSU shall be fully vested (and </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the shares subject to any such TBRSU shall be delivered no later than sixty (60) days following such termination of Service). (Nothing in the preceding sentence shall limit or alter the Executive&#8217;s rights under Section 6(c) hereof in the event that the Exe</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cutive instead terminates his or her Service by reason of a Qualified Termination.) In the event that a Change in Control occurs in which outstanding Options, shares of TBRS, and/or TBRSUs are not being assumed, continued or substituted (as contemplated by</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the preceding sentence), any Option and the unvested portion of any TBRS and any TBRSU shall be treated in accordance with the default rules applicable under Section 17.3 of the 2012 LTIP (or if made pursuant to a successor long-term incentive plan or ind</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ucement plan, the default rules contained in such plan).&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Definition of Qualified Retirement</font>.&nbsp;&nbsp;The term Qualified Retirement as used in any award agreement with respect to Options, TBRS, or TBRSU shall, notwithstanding any definition of such phrase in an award agreement, be defined as set forth in this Agreement. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Survival</font>.&nbsp;&nbsp;All of the provisions in this Section&#160;6 shall survive any expiration or termination of this Agreement for any reason (unless such termination is as a result of a future novation of such provisions entered into by each of the parties).&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU12"></a>7.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Section 280G</font>.&nbsp;&nbsp;In the event that any of the severance payments and other benefits provided by this Agreement or otherwise payable to Executive (a)&#160;constitute &#8220;parachute payments&#8221; within the meaning of Section&#160;280G of the Code, and (b)&#160;but for this Section 7, would be subject to the excise tax imposed by Section&#160;4999 of the Code (&#8220;<font style="text-decoration:underline;">Excise Tax</font>&#8221;), then Executive&#8217;s severance payments and benefits under this Agreement or otherwise shall be payable either in full or in such lesser amount which would result in no portion of such severance payments or benefits being subject to the Excise Tax, whichever of the foregoing amounts, taking into account the applicable federal, state and local income and employment taxes and the Excise Tax, results in the receipt by Executive, on an after-tax basis, of the greatest amount of severance payments and benefits under this Agreement or otherwise, notwithstanding that all or some portion of such severance payments or benefits may be taxable under Section&#160;4999 of the Code.&nbsp;&nbsp;Any reduction in the severance payments and benefits required by this Section 7 shall be made in the following order: (i)&#160;reduction of cash payments; (ii)&#160;reduction of accelerated vesting of equity awards other than stock options; (iii)&#160;reduction of accelerated vesting of stock options; and (iv)&#160;reduction of other benefits paid or provided to Executive.&nbsp;&nbsp;The calculations and </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in Control and Severance Agreement&#8212;Jon Serbousek</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective Date:&nbsp;&nbsp;November 1, 2019<font style="margin-left:36pt;">Page </font>11</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;"></font>&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">establishment of assumptions in this Section&#160;7 will be performed by a professional tax fi</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rm engaged by the Company as of the day prior to the CiC Date.&nbsp;&nbsp;If the tax firm so engaged by the Company is serving as accountant or auditor for the acquiring company, the Company shall appoint a nationally recognized tax firm to make the determinations r</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">equired by this Section 7.&nbsp;&nbsp;The Company shall bear all expenses with respect to the determinations by such firm required to be made by this Section 7.&nbsp;&nbsp;The Company and Executive shall furnish such tax firm such information and documents as the tax firm may</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> reasonably request in order to make its required determination.&nbsp;&nbsp;The tax firm will provide its calculations, together with detailed supporting documentation, to the Company and Executive as soon as practicable following its engagement.&nbsp;&nbsp;Any good faith det</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">erminations of the tax firm made hereunder shall be final, binding and conclusive upon the Company and Executive.&nbsp;&nbsp;However, the Executive shall have the final authority to make any good faith determination(s) associated with the assumptions used by the tax</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> firm in providing its calculations, and such good faith determination by the Executive shall be binding on the Company.&nbsp;&nbsp;As a result of the uncertainty in the application of Sections 409A, 280G or 4999 of the Code at the time of the initial determination </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by the professional tax firm described in this Section 7, it is possible that the Internal Revenue Service (the &#8220;</font><font style="text-decoration:underline;">IRS</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;) or other agency will claim that an Excise Tax greater than that amount, if any, determined by such professional firm for the purposes of </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">this Section 7 is due (the &#8220;</font><font style="text-decoration:underline;">Additional Excise Tax</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;).&nbsp;&nbsp;Executive shall notify the Company in writing of any claim by the IRS or other agency that, if successful, would require payment of Additional Excise Tax.&nbsp;&nbsp;Executive and the Company shall each reasonabl</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">y cooperate with the other in connection with any administrative or judicial proceedings concerning the existence or amount of liability for Excise Tax with respect to payments made or due to Executive.&nbsp;&nbsp;The Company shall pay all reasonable fees, expenses </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and penalties of Executive relating to a claim by the IRS or other agency.&nbsp;&nbsp;In the event it is finally determined that a further reduction would have been required under this Section 7 to place Executive in a better after-tax position, Executive shall repa</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">y the Company such amount within 30&#160;days thereof in order to effect such result.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Section 409A</font>. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>For purposes of Section 409A of the Code (&#8220;<font style="text-decoration:underline;">Section 409A</font>&#8221;) (i)&#160;each &#8220;payment&#8221; (as defined by Section 409A) made under this Agreement shall be considered a &#8220;separate payment,&#8221; and (ii)&#160;payments shall be deemed exempt from the definition of deferred compensation under Section 409A to the fullest extent possible under (x)&#160;the &#8220;short-term deferral&#8221; exemption of Treasury Regulation &#167;&#160;1.409A-1(b)(4), and (y)&#160;with respect to amounts paid as separation pay (as defined under Treasury Regulation &#167; 1.409A-1(m)) no later than the second calendar year following the calendar year containing the Executive&#8217;s &#8220;separation from service&#8221; (as defined for purposes of Section 409A), the &#8220;two years/two-times&#8221; separation pay exemption of Treasury Regulation &#167; 1.409A-1(b)(9)(iii), which exemptions are hereby incorporated by reference.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>Any payments otherwise payable under this Agreement shall not commence until the Executive has a &#8220;separation from service&#8221; (as defined in Section 409A).&nbsp;&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in Control and Severance Agreement&#8212;Jon Serbousek</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective Date:&nbsp;&nbsp;November 1, 2019<font style="margin-left:36pt;">Page </font>12</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;"></font>&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU13"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font><font style="margin-left:36pt;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the Executive is a &#8220;specified employee&#8221; as defined in Section 409A (and as applied according to pr</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ocedures of the Company and its affiliates) as of the Executive&#8217;s separation from service, to the extent any payment under this Agreement constitutes deferred compensation (after taking into account any applicable exemptions from Section 409A) that is paya</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ble upon a separation from service, and to the extent required in order to avoid the imposition of an excise tax under Section 409A, no payments due under this Agreement may be made until the earlier of:&nbsp;&nbsp;(1)&#160;the date of the Executive&#8217;s death and (2) the f</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">irst day of the seventh month following the Executive&#8217;s separation from service, provided, however, that any payments delayed during this six-month period shall be paid in the aggregate in a lump sum on the first day of the seventh month following the Exec</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">utive&#8217;s separation from service (or upon the date of the Executive&#8217;s death, if earlier).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font>Any expense reimbursements or in kind benefits under this Agreement that constitute deferred compensation within the meaning of Section 409A shall be made or provided in accordance with the requirements of Section 409A, including, without limitation, that: (i) the expenses eligible for reimbursement or the amount of in-kind benefits provided in one taxable year shall not affect the expenses eligible for reimbursement or the amount of in-kind benefits provided in any other taxable year; (ii) the reimbursement of an eligible expense shall be made no later than the end of the year after the year in which such expense was incurred; and (iii) the right to reimbursement or in-kind benefits shall not be subject to liquidation or exchange for another benefit.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:36pt;"></font>If this Agreement fails to meet the requirements of Section 409A, neither the Company nor any of its affiliates shall have any liability for any tax, penalty or interest imposed on the Executive by Section 409A, and the Executive shall have no recourse against the Company or any of its affiliates for payment of any such tax, penalty, or interest imposed by Section 409A.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Restrictive Covenants</font>.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Non-Disparagement</font>.&nbsp;&nbsp;The Executive agrees that the Company&#8217;s reputation and goodwill in the marketplace is of utmost importance and value to the Company.&nbsp;&nbsp;The Executive further agrees that during and after the term of the Executive&#8217;s employment with the Company, the Executive will not make, publish or cause to be published any public or private statement or comments disparaging or defaming the Company, its subsidiaries or affiliates, or any of their respective stockholders, partners, members, directors, managers, officers and employees.&nbsp;&nbsp;The Executive acknowledges and agrees that this prohibition extends to statements, written or verbal, made to anyone, including but not limited to, the news media, competitors, vendors, and employees (past and present).&nbsp;&nbsp;The Executive further understands and agrees that this Section 9(a) is a material provision of this Agreement and that any breach of this Section 9(a) shall be a material breach of this Agreement, and that the Company would be irreparably harmed by violation of this provision.&nbsp;&nbsp;<font style="color:#000000;">This prohibition does not preclude the Executive from providing truthful testimony if compelled by law.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in Control and Severance Agreement&#8212;Jon Serbousek</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective Date:&nbsp;&nbsp;November 1, 2019<font style="margin-left:36pt;">Page </font>13</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;"></font>&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU14"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Cooperation</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Executive agrees that after the Executive&#8217;s date of termination, the Executive shall make the Executive available at reasonable times, intervals a</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nd places for interviews, consultations, internal investigations and/or testimony during which the Executive shall provide to the Company, or its designated attorneys or agents, any and all information known to the Executive regarding or relating to the Co</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mpany or the Executive&#8217;s activities on behalf of the Company pertaining to the subject matter on which the Executive&#8217;s cooperation is sought.&nbsp;&nbsp;The Executive agrees to remain involved for so long as any such matters shall be pending.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Non-Disclosure</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;"></font>During the course of the Executive&#8217;s employment with the Company, before and after the execution of this Agreement, and as consideration for the restrictive covenants entered into by the Executive herein, the Executive has received and will continue to receive some or all of the Company&#8217;s various Trade Secrets (as defined under applicable law) and confidential or proprietary information, which includes the following whether in physical or electronic form: (1)&#160;data and compilations of data related to, Business Opportunities (as defined below), (2)&#160;computer software, hardware, network and internet technology utilized, modified or enhanced by the Company or by the Executive in furtherance of the Executive&#8217;s duties with the Company; (3)&#160;compilations of data concerning Company products, services, customers, and end users including but not limited to compilations concerning projected sales, new project timelines, inventory reports, sales, and cost and expense reports; (4)&#160;compilations of information about the Company&#8217;s employees and independent contracting consultants; (5)&#160;the Company&#8217;s financial information, including, without limitation, amounts charged to customers and amounts charged to the Company by its vendors, suppliers, and service providers; (6)&#160;proposals submitted to the Company&#8217;s customers, potential customers, wholesalers, distributors, vendors, suppliers and service providers; (7)&#160;the Company&#8217;s marketing strategies and compilations of marketing data; (8)&#160;compilations of data or information concerning, and communications and agreements with, vendors, suppliers and licensors to the Company and other sources of technology, products, services or components used in the Company&#8217;s business; (9)&#160;the Company&#8217;s research and development records and data; and (10)&#160;any summary, extract or analysis of such information together with information that has been received or disclosed to the Company by any third party as to which the Company has an obligation to treat as confidential (collectively, &#8220;<font style="text-decoration:underline;">Confidential Information</font>&#8221;). &#8220;<font style="text-decoration:underline;">Business Opportunities</font>&#8221; shall mean all ideas, concepts or information received or developed (in whatever form) by the Executive concerning any business, transaction or potential transaction that constitutes or may constitute an opportunity for the Company to earn a fee or income, specifically including those relationships that were initiated, nourished or developed at the Company&#8217;s expense. Confidential Information does not include data or information: (1)&#160;which has been voluntarily disclosed to the public by the Company, except where such public disclosure has been made by the Executive without authorization from the Company; (2)&#160;which has been independently developed and disclosed by others; or (3)&#160;which has otherwise entered the public domain through lawful means.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in Control and Severance Agreement&#8212;Jon Serbousek</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective Date:&nbsp;&nbsp;November 1, 2019<font style="margin-left:36pt;">Page </font>14</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;"></font>&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU15"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font><font style="margin-left:36pt;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All Confidential Information, Trade Secrets, and all physical and electronic embodiments thereof are confidential and are and will remain the sole and exclusive property of the Company. During and after the term of the Executive&#8217;s employment with </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Company, the Executive agrees that the Executive shall protect any such Confidential Information and Trade Secrets and shall not, except in connection with the performance of the Executive&#8217;s remaining duties for the Company, use, disclose or otherwise </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">copy, reproduce, distribute or otherwise disseminate any such Confidential Information or Trade Secrets, or any physical or electronic embodiments thereof, to any third party; provided, however, that the Executive may make disclosures required by a valid o</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rder or subpoena issued by a court or administrative agency of competent jurisdiction, in which event the Executive will promptly notify the Company of such order or subpoena to provide the Company an opportunity to protect its interests.&nbsp;&nbsp;Without limiting</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the generality of the foregoing, the Executive agrees that after the Executive&#8217;s termination of employment with the Company, the Executive shall not disclose to any third party any transaction or potential transaction that was under active consideration b</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">y the Company on or during the six (6) month period prior to the Executive&#8217;s date of termination from the Company.&nbsp;&nbsp;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Executive further agrees that if the Executive is ever subpoenaed or otherwise required by law to provide any statement or other assista</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nce to a party to a dispute or litigation with the Company, other than the Company, then the Executive shall provide written notice of the circumstances requiring such statement or other assistance, including where applicable a copy of the subpoena or othe</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">r legal writ, in such a manner and at such a time that allows the Company to timely respond.&nbsp;&nbsp;Nothing herein shall prevent the Executive from cooperating with co-defendants in litigation or with inquiry in a government investigation without a need to obtai</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n prior consent or approval from the Company; provided, however, the Executive shall provide prompt notice of any voluntary giving of oral or written statements to such parties, and provide to the Company a copy of any written statement so given or a summa</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ry of any oral statement provided.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)<font style="margin-left:36pt;"></font>Upon request by the Company and, in any event, upon termination of the Executive&#8217;s employment with the Company for any reason, the Executive will promptly deliver to the Company (within twenty-four (24)&#160;hours) all property belonging to the Company, including but without limitation, all Confidential Information, Trade Secrets and all electronic and physical embodiments thereof, all Company files, customer lists, management reports, memoranda, research, Company forms, financial data and reports and other documents (including but not limited to all such data and documents in electronic form) supplied to or created by the Executive in connection with the Executive&#8217;s employment with the Company (including all copies of the foregoing) in the Executive&#8217;s possession or control, and all of the Company&#8217;s equipment and other materials in the Executive&#8217;s possession or control. The Executive agrees to allow the Company, at its request, to verify return of Company property and documents and information and/or permanent deletion of the same, through inspection of personal computers, personal storage media, third party websites, third party e-mail systems, personal digital assistant devices, cell phones and/or social networking sites on which Company information was stored during the Executive&#8217;s employment with the Company.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in Control and Severance Agreement&#8212;Jon Serbousek</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective Date:&nbsp;&nbsp;November 1, 2019<font style="margin-left:36pt;">Page </font>15</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;"></font>&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU16"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iv)</font><font style="margin-left:36pt;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nothing contained herein shall be in derogation or a limitation of the rights of the Company to enforce its rights or the Executive&#8217;s duties under the applicable law relat</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ing to Trade Secrets.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(v)<font style="margin-left:36pt;"></font>Notwithstanding anything to the contrary contain herein, the parties hereto acknowledge that pursuant to 18 USC &#167; 1833(b), the Executive may not be held liable under any criminal or civil federal or state trade secret law for disclosure of a trade secret: (i) made in confidence to a government official, either directly or indirectly, or to an attorney, solely for the purpose of reporting or investigating a suspected violation of law or (ii) in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. &#160;Additionally, the parties hereto acknowledge that if the Executive sues the Company for retaliation based on the reporting of a suspected violation of law, the Executive may disclose a trade secret to the Executive&#8217;s attorney and use the trade secret information in the court proceeding, so long as any document containing the trade secret is filed under seal and the Executive does not disclose the trade secret except pursuant to court order.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Innovations</font>.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;"></font>The Executive hereby assigns, transfers and conveys to Orthofix Inc. and its successors and assigns any and all inventions, processes, procedures, systems, discoveries, designs, configurations, technology, works of authorship, trade secrets and improvements (whether or not they are made, conceived or reduced to practice during working hours or using the Company&#8217;s data or facilities) (collectively, &#8220;<font style="text-decoration:underline;">Innovations</font>&#8221;) which the Executive makes, conceives, reduces to practice or otherwise acquires during any period of his/her employment by the Company (either solely or jointly with others), and which are related to the Company&#8217;s present or planned business, the Company&#8217;s services or products, and any and all patents, copyrights, trademarks, trade names and applications therefor, in the United States and elsewhere, relating thereto.&nbsp;&nbsp;The Innovations shall be the sole property of Orthofix Inc. and shall at all times be held by the Executive in a fiduciary capacity for the sole benefit of Orthofix Inc.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)<font style="margin-left:36pt;"></font> All such Innovations that consist of works of authorship capable of protection under copyright laws shall be prepared by the Executive as works made for hire, with the understanding that Orthofix Inc. shall own all of the exclusive rights to such works of authorship under the United States copyright law and all international copyright conventions and foreign laws.&nbsp;&nbsp;The foregoing notwithstanding, to the extent that any such Innovation is not deemed a work made for hire, the Executive hereby assigns to Orthofix Inc. such Innovation and any and all patents, copyrights, trademarks, trade names and applications therefor, in the United States and elsewhere, relating thereto.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU17"></a>(iii)<font style="margin-left:36pt;"></font>The Executive shall maintain adequate and current written records of all such Innovations, which shall be available to and remain the sole property of Orthofix Inc. at all times.&nbsp;&nbsp;The Executive shall promptly disclose to the Company all such Innovations and shall assist the Company in obtaining and enforcing for its own benefit patents and copyright registrations on and in respect of such Innovations in all countries in all ways that the Company </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in Control and Severance Agreement&#8212;Jon Serbousek</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective Date:&nbsp;&nbsp;November 1, 2019<font style="margin-left:36pt;">Page </font>16</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;"></font>&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may request, to secure and enjoy the full benefits and advantages of such Innovations.&nbsp;&nbsp;The Executive understands that his/her obligations under this s</font>ect<font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on shall continue after the termination of the Executive&#8217;s employment by the Company.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_32"></a>(e)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Non-Solicitation</font>.&nbsp;&nbsp;The Executive agrees that during the course of the Executive&#8217;s employment with the Company and for a period of eighteen (18) months following the termination of the Executive&#8217;s employment with the Company for any reason, with or without Cause, whether upon the initiative of either the Executive or the Company, the Executive will not, on behalf of the Executive or any other individual, corporation, partnership, limited liability company, association, trust or any other entity or organization (including a government or political subdivision or an agency or instrumentality thereof), directly or by assisting others, solicit, induce, persuade or encourage, or attempt to solicit, induce, persuade or encourage, any individual employed by the Company, with whom the Executive has worked, to terminate such employee&#8217;s position with the Company, whether or not such employee is a full-time or temporary employee o<a name="_cp_text_1_32"></a>f the Company and whether or not such employment is pursuant to a written agreement, for a determined period, or at will. The provisions of this Section 9(e) shall only apply to the Executive&#8217;s solicitation or attempted solicitation of those individuals employed by the Company at the time of solicitation or attempted solicitation. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Non-Competition</font>.&nbsp;&nbsp;Without the prior written consent of the Board (which may be withheld in the Board&#8217;s sole discretion), so long as the Executive is an employee of the Company and for a period of eighteen (18) months thereafter, the Executive agrees that the Executive shall not anywhere in the Prohibited Area, for the Executive&#8217;s own account or the benefit of any other, engage or participate in or assist or otherwise be connected with a Competing Business.&nbsp;&nbsp;For the avoidance of doubt, the Executive understands that this Section 9(f) prohibits the Executive from acting for himself or as an officer, employee, manager, operator, principal, owner, partner, shareholder, advisor, consultant of, or lender to, any individual or other Person that is engaged or participates in or carries out a Competing Business or is actively planning or preparing to enter into a Competing Business.&nbsp;&nbsp;The parties agree that such prohibition shall not apply to the Executive&#8217;s passive ownership of not more than 5% of a publicly-traded company.&nbsp;&nbsp;For purposes of the foregoing, (i) &#8220;<font style="text-decoration:underline;">Competing Business</font>&#8221; shall mean any business or activity that (i) competes with the Company and involves (ii) (A) the same or substantially similar types of products or services (individually or collectively) manufactured, marketed or sold by the Company after the Effective Date or (B) products or services so similar in nature to that of the Company&#8217;s (or that the Company will soon thereafter offer) that they would be reasonably likely to displace substantial business opportunities or customers of the Company, and (ii) &#8220;<font style="text-decoration:underline;">Prohibited Area</font>&#8221; shall mean North America, South America and Europe, which Prohibited Area the parties have agreed to as a result of the fact that those are the geographic areas in which the Company conducts a preponderance of its business and in which the Executive provides substantive services to the benefit of the Company. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU18"></a>(g)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Acknowledgements</font>.&nbsp;&nbsp;The Executive acknowledges that the Company is in the business of providing reconstructive, regenerative and trauma-related products used in various orthopedic and spine procedures worldwide and that the Company makes substantial investments and has established substantial goodwill associated with its business, supplier </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in Control and Severance Agreement&#8212;Jon Serbousek</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective Date:&nbsp;&nbsp;November 1, 2019<font style="margin-left:36pt;">Page </font>17</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;"></font>&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">relationships and marketing programs throughout the United States.&nbsp;&nbsp;The Executive therefore acknowledges and agrees that it is fair and reasonable for the Company to take steps to protect its Confidential Information, T</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rade Secrets, goodwill, business relationships, employees, economic advantages, and/or other legitimate business interests from the risk of misappropriation of or harm to its Confidential Information, Trade Secrets, goodwill, business relationships, employ</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ees, economic advantages, and/or other legitimate business interests.&nbsp;&nbsp;The Executive acknowledges that any limitations as to time and scope of activity to be restrained are reasonable and do not impose a greater restraint than is necessary to protect Compa</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ny&#8217;s Confidential Information, Trade Secrets, good will, business relationships, employees, economic advantages, and/or other legitimate business interests, and will not prevent the Executive from earning a livelihood.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(h)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Survival of Covenants</font>.&nbsp;&nbsp;The provisions and restrictive covenants in this Section 9 shall survive the expiration or termination of this Agreement for any reason.&nbsp;&nbsp;The Executive agrees not to challenge the enforceability or scope of the provisions and restrictive covenants in this Section 9.&nbsp;&nbsp;The Executive further agrees to notify all future persons or businesses, with which the Executive becomes affiliated or employed by, of the provisions and restrictions set forth in this Section 9, prior to the commencement of any such affiliation or employment.&nbsp;&nbsp;If any of the provisions in this Section 9 are construed to be invalid or unenforceable in any respect, the parties agree that the same may be modified as the court may direct to make such provisions and covenants reasonable, and such modification shall not affect the remainder of such provision, and such provisions shall be given the maximum possible effect and the modified agreement shall be fully enforceable.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Injunctive Relief</font>. The Executive acknowledges that if the Executive breaches or threatens to breach any of the provisions of this Agreement, the Executive&#8217;s actions will cause irreparable harm and damage to the Company which cannot be compensated by damages alone. Accordingly, if the Executive breaches or threatens to breach any of the provisions of this Agreement, the Company shall be entitled to injunctive relief, in addition to any other rights or remedies the Company may have. The Executive hereby waives the requirement for a bond by the Company as a condition to seeking injunctive relief.&nbsp;&nbsp;The existence of any claim or cause of action by the Executive against the Company, whether predicated on this Agreement or otherwise, shall not constitute a defense to the enforcement by the Company of the Executive&#8217;s agreements under this Agreement.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Entire Agreement</font>.&nbsp;&nbsp;The parties agree that this Agreement shall constitute a novation of such the Prior CiC Agreement, and that, effective upon execution and delivery of this Agreement, (i) the Prior CiC Agreement shall be deemed null and void, with no parties thereunder continuing to be bound by any obligations under the Prior CiC Agreement, and (ii) this Agreement shall amend and supersede all rights and obligations set forth in the Prior CiC Agreement. This Agreement also supersedes any and all other agreements, either oral or in writing, between the parties hereto with respect to severance payments and benefits, and contains all of the agreements between the parties with respect to severance payments and benefits.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in Control and Severance Agreement&#8212;Jon Serbousek</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective Date:&nbsp;&nbsp;November 1, 2019<font style="margin-left:36pt;">Page </font>18</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;"></font>&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU19"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Miscellaneous</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_48"></a><a name="_cp_text_2_49"></a><a name="_cp_text_1_50"></a><a name="_cp_text_2_52"></a><a name="_cp_text_1_53"></a><a name="_cp_text_1_54"></a><a name="_cp_text_1_55"></a>(a)<font style="margin-left:36pt;"></font><a name="_cp_text_1_48"></a>Except for injunctive relief as set forth herein, the parties agree that any dispute or controversy arising under or in connection with this Agreement shall be resolved exclusively and finally by binding arbitration in Lewisville, Texas, before a single ar<a name="_cp_text_2_49"></a><a name="_cp_text_1_50"></a>bitrator, with such arbitration to be conducted in accordance with the rules of the American Arbitration <a name="_cp_text_2_52"></a><a name="_cp_text_1_53"></a>Association&#8217;s Commercial Arbitration Rules then in effect.&nbsp;&nbsp;Judgment on the arbitrator&#8217;s award may be entered by any court having jurisdiction.&nbsp;&nbsp;The Co<a name="_cp_text_1_54"></a>mpany shall be responsible for its own <a name="_cp_text_1_55"></a>attorneys&#8217; fees, costs and expenses and shall pay to the Executive an amount equal to all reasonable attorneys&#8217; and related fees, costs and expenses incurred by the Executive in connection with such arbitration and entry of judgment, but only if the arbitrator determines that the Executive prevailed on a material issue of the arbitration.&nbsp;&nbsp;If there is any dispute between the Company and the Executive as to the payment of such fees and expenses, the arbitrator shall resolve such dispute, which resolution shall also be final and binding on the parties, and as to such dispute only, the burden of proof shall be on the Company.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_57"></a><a name="_cp_text_1_58"></a><a name="_cp_text_2_62"></a><a name="_cp_text_1_63"></a><a name="_cp_text_2_64"></a><a name="_cp_text_1_65"></a>(b)<font style="margin-left:36pt;"></font>This Agreement shall be governed, construed and interpreted in accordance with the laws of the Sta<a name="_cp_text_1_57"></a>te of Texas (without regard to any provision of that State&#8217;s rules on the conflicts of law that might make applicable the law of a jurisdiction other than that of the State of Texas). Subject to Section 11(a) hereof, all actions or proceedings for injuncti<a name="_cp_text_1_58"></a>ve relief arising out of this Agreement shall exclusively be heard and determined in state or federal courts in the State of Texas having appropriate jurisdiction for Collin County, Texas.&nbsp;&nbsp;The parties expressly consent to the exclusive jurisdiction of suc<a name="_cp_text_2_62"></a><a name="_cp_text_1_63"></a>h courts in any such action or proceeding and waive any objection to venue therein and any <a name="_cp_text_2_64"></a><a name="_cp_text_1_65"></a>defense of forum non conveniens.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font>This Agreement may be executed in any number of counterparts, each of which, when executed by both parties to this Agreement shall be deemed to be an original, and all of which counterparts together shall constitute one and the same instrument.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font>The failure of either party hereto to enforce any right under this Agreement shall not be construed to be a waiver of that right, or of damages caused thereby, or of any other rights under this Agreement.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:36pt;"></font>This Agreement may not be amended or modified otherwise than by a written agreement executed by the parties hereto or their respective successors and legal representatives. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU20"></a>(f)<font style="margin-left:36pt;"></font>This Agreement shall inure to the benefit of and be binding upon the Company and its successors and assigns.&nbsp;&nbsp;This Agreement shall bind any successor of or to the Company, its assets or its businesses (whether direct or indirect, by purchase, merger, consolidation or otherwise), in the same manner and to the same extent that the Company would be obligated under this Agreement if no succession had taken place.&nbsp;&nbsp;In the case of any transaction in which a successor would not by the foregoing provision or by operation of law be bound by this Agreement, the Company shall require such successor expressly and unconditionally to assume and agree to perform the Company&#8217;s obligations under this </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in Control and Severance Agreement&#8212;Jon Serbousek</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective Date:&nbsp;&nbsp;November 1, 2019<font style="margin-left:36pt;">Page </font>19</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;"></font>&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Agreement, in the same manner and to the same extent that the Company would be required to </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">perform if no such succession had taken place.&nbsp;&nbsp;All rights under this Agreement are personal to the Executive and, without the prior written consent of the Company, shall not be assignable by the Executive otherwise than by shall or the laws of descent and</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> distribution.&nbsp;&nbsp;This Agreement shall inure to the benefit of and be enforceable in the event of the Executive&#8217;s death or disability by the Executive&#8217;s legal representatives, heirs and legatees.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(g)<font style="margin-left:36pt;"></font>The Executive and the Company acknowledge that the employment of the Executive by the Company is &#8220;at will&#8221; and may be terminated by either the Executive or the Company at any time.&nbsp;&nbsp;Nothing contained in the Agreement shall affect such rights to terminate, provided, however, that nothing in this Section 11(g) shall prevent the Executive from receiving any amounts payable pursuant to Sections 3 or 4 hereof in the event of a termination described in such Sections.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(h)<font style="margin-left:36pt;"></font>Notwithstanding anything in this Agreement to the contrary, in no event shall anything in this Agreement (whether in Section 9 or otherwise) be interpreted to limit or restrict the Executive&#8217;s right or ability to provide whistleblower information to the Securities and Exchange Commission regarding violations of the federal securities laws pursuant to Section 21F of the Exchange Act.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;"></font>Any provision in this Agreement which is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective only to the extent of such prohibition or unenforceability without invalidating or affecting the remaining provisions hereof, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(j)<font style="margin-left:36pt;"></font>Notices and all other communications contemplated by this Agreement shall be in writing and shall be deemed to have been duly given when personally delivered or when mailed by U.S. registered or certified mail, return receipt requested and postage prepaid or when sent by express U.S. mail or overnight delivery through a national delivery service (or an international delivery service in the case of an address outside the U.S.) with signature required.&nbsp;&nbsp;Notice to the Company shall be directed to the attention of the General Counsel of the Company at the address of the Company&#8217;s headquarters, and notice to the Executive shall be directed to the Executive at the Executive&#8217;s most recent personal residence on file with the Company.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(k)<font style="margin-left:36pt;"></font>The Company shall deduct from the amounts payable to the Executive pursuant to this Agreement all required withholding amounts and deductions, including but not limited to federal, state and local withholding amounts in accordance all applicable laws and regulations and deductions authorized by the Executive.&nbsp;&nbsp;The Executive shall be solely responsible for and shall pay all taxes associated with the amounts payable under this Agreement.&nbsp;&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU21"></a><a name="_AEIOULastRenderedPageBreakAEIOU22"></a><br /></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in Control and Severance Agreement&#8212;Jon Serbousek</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective Date:&nbsp;&nbsp;November 1, 2019<font style="margin-left:36pt;">Page </font>20</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; </p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">each of the undersigned has executed this Agreement as of the date first above written.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:41.54%;width:60.77%;">
<tr>
<td style="width:60.77%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ORTHOFIX MEDICAL INC.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:&nbsp;&nbsp;/s/ Ronald A. Matricaria</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ronald A. Matricaria</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chairman of the Board of Directors</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXECUTIVE</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Jon Serbousek</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jon Serbousek</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in Control and Severance Agreement&#8212; Jon Serbousek</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective Date:&nbsp;&nbsp;November 1, 2019<font style="margin-left:36pt;">Page </font>21</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; </p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU23"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT A</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Release</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You, for yourself, your spouse and your agents, successors, heirs, executors, administrators and assigns, hereby irrevocably and unconditionally forever release and discharge Orthofix Medical Inc., a Delaware corporation, and its direct and indirect subsidiaries (all such entities, collectively, the &#8220;<font style="text-decoration:underline;">Company</font>&#8221;), its parents, divisions and affiliates and its and their current and former owners, directors, officers, stockholders, insurers, benefit plans, representatives, agents and employees, and each of their predecessors, successors, and assigns (collectively, the &#8220;<font style="text-decoration:underline;">Releasees</font>&#8221;), from any and all actual or potential claims or liabilities of any kind or nature, including, but not limited to, any claims arising out of or related to your employment and separation from employment with the Company and any services that you provided to the Company; any claims for salary, commissions, bonuses, other severance pay, vacation pay, allowances or other compensation, or for any benefits under the Employee Retirement Income Security Act of 1974 (&#8220;<font style="text-decoration:underline;">ERISA</font>&#8221;) (except for vested ERISA benefits); any claims for discrimination, harassment or retaliation of any kind or based upon any legally protected classification or activity; any claims under Title VII of the Civil Rights Acts of 1964, the Civil Rights Act of 1866 and 1964, as amended, 42 U.S.C. &#167; 1981, the Age Discrimination in Employment Act, the Older Workers Benefit Protection Act, the Americans with Disabilities Act, 42 U.S.C. &#167;1981, 42 U.S.C. &#167; 1983, the Family Medical Leave Act and any similar state law, the Fair Credit Reporting Act and any similar state law, the Fair Credit Reporting Act, 15 U.S.C. &#167; 1681, et seq., the Worker Adjustment and Retraining Notification Act, 29 U.S.C. &#167; 2101, et seq., the Equal Pay Act and any similar state law, as well as any amendments to any such laws; any claims for any violation of any federal or state constitutions or executive orders; any claims for wrongful or constructive discharge, violation of public policy, breach of contract or promise (oral, written, express or implied), personal injury not covered by workers&#8217; compensation benefits, misrepresentation, negligence, fraud, estoppel, defamation, infliction of emotional distress, contribution and any claims under any other federal, state or local law, including those not specifically listed in this Release, that you, your heirs, executors, administrators, successors, and assigns now have, ever had or may hereafter have, whether known or unknown, suspected or unsuspected, up to and including the date of your execution of this Release.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU24"></a>For the purpose of implementing a full and complete release and discharge of the Releasees as set forth above, you acknowledge that this Release is intended to include in its effect, without limitation, all claims known or unknown that you have or may have against the Releasees which arise out of or relate to your employment, including but not limited to compensation, performance or termination of employment with the Company, except for, and notwithstanding anything in this Release to the contrary, claims which cannot be released solely by private agreement.&nbsp;&nbsp;This Release also excludes any claims relating to any right you may have to payments pursuant to Sections 3 or 4 of the Change in Control and Severance Agreement, entered into as of November 1, 2019, by and between the Company and me, any claim for workers&#8217; compensation benefits and any rights you may have to indemnification or directors&#8217; and officers&#8217; liability insurance under the Company&#8217;s articles of association, certificates of </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in Control and Severance Agreement&#8212; Jon Serbousek</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective Date:&nbsp;&nbsp;November 1, 2019<font style="margin-left:36pt;">Page </font>22</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">incorporation or bylaws, a</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ny indemnification agreement to which you are a party or beneficiary or applicable law, as a result of having served as an officer, director or employee of the Company or any of its affiliates.&nbsp;&nbsp;You further acknowledge and agree that you have received all </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">leave, compensation and reinstatement benefits to which you were entitled through the date of your execution of this Release, and that you were not subjected to any improper treatment, conduct or actions as a result of a request for leave, compensation or </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reinstatement.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You affirm, by signing this Release, that you have not suffered any unreported injury or illness arising from your employment, and that you have not filed, with any federal, state, or local court or agency, any actions or charges against the Releasees relating to or arising out of your employment with or separation from the Company.&nbsp;&nbsp;You further agree that while this Release does not preclude you from filing a charge with the National Labor Relations Board (&#8220;<font style="text-decoration:underline;">NLRB</font>&#8221;), the Equal Employment Opportunity Commission (&#8220;<font style="text-decoration:underline;">EEOC</font>&#8221;), or a similar federal, state or local agency, or from participating in any investigation or proceeding with them, you do waive your right to personally recover monies or reinstatement as a result of any complaint or charge filed against the&nbsp;&nbsp;Company with the NLRB, EEOC, or any federal, state or local court or agency.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M28"></a><a name="_DV_M30"></a>You understand that the claims released in this Release do <font style="text-decoration:underline;">not</font> include claims by you for: (1) unemployment insurance; (2) worker&#8217;s compensation benefits; (3) st<a name="_DV_M28"></a><a name="_DV_M30"></a>ate disability compensation; (4) previously vested benefits under any Company-sponsored benefits plan; and (5) any other rights that cannot by law be released by private agreement.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You acknowledge:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">That you were provided forty-five (45) full days during which to consider whether to sign this Release.&nbsp;&nbsp;If you have signed this Agreement prior to the expiration of the forty-five (45)-day period, you have voluntarily elected to forego the remainder of that period. </p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">That you have carefully read and fully understand all of the terms of this Release.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">That you understand that by signing this Release, you are waiving your rights under the Age Discrimination in Employment Act, as amended by the Older Workers Benefit Protection Act, 29 U.S.C. &#167; 621, et seq., and that you are not waiving any rights arising after the date that this Release is signed.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">That you have been given an opportunity and have been advised to consult with anyone you choose, including an attorney, about this Release.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_AEIOULastRenderedPageBreakAEIOU25"></a>That you understand fully the terms and effect of this Release and know of no claim that has not been released by this Release.&nbsp;&nbsp;And, you further acknowledge that you are not aware of, or that you have fully disclosed to the Company, any matters for which you are responsible or which has come to your attention as an employee of the Company that might give rise to, evidence, or support any claim </p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in Control and Severance Agreement&#8212;Jon Serbousek</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective Date:&nbsp;&nbsp;November 1, 2019<font style="margin-left:36pt;">Page </font>23</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of illegal conduct, regulatory violation, unlawful discrimination, or other cause of action against the Company.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">That you have made full and truthful disclosures to the Company&#8217;s compliance department regarding any misconduct (including any violations of federal securities laws) relating to the Company or its subsidiaries of which you are aware, and that you understand that notwithstanding anything herein or in any other agreement to the contrary, in no event shall you be prohibited or limited from my right to provide truthful information to or otherwise assist U.S. governmental authorities in any investigation regarding the Company (whether pursuant to Section 21F of the Securities Exchange Act of 1934, as amended (the &#8220;<font style="text-decoration:underline;">Exchange Act</font>&#8221;), or otherwise), and in the event of such assistance, nothing herein or in any other agreement shall be deemed to conflict with my right to receive any award payable pursuant to Section 21F of the Exchange Act.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(g)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">That these terms are final and binding on you.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(h)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">That you have signed this Release voluntarily, and not in reliance on any representations or statements made to you by any employee or officer of the Company or any of its subsidiaries.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">That you have seven (7) days following your execution of this Release to revoke it in writing, and that this Release is not effective or enforceable until after this seven (7) day period has expired without revocation.&nbsp;&nbsp;If you wish to revoke this Release after signing it, you must provide written notice of your decision to revoke this Release to the Company, to the attention of the General Counsel of the Company at the address of the Company&#8217;s headquarters, by no later than 11:59 p.m. on the seventh calendar day after the date on which you have signed this Release. </p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PLEASE READ CAREFULLY.&nbsp;&nbsp;THIS RELEASE INCLUDES A RELEASE OF ALL KNOWN AND UNKNOWN CLAIMS.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ACKNOWLEDGED AND AGREED</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">____________________________________________________</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jon Serbousek<font style="margin-left:36pt;">Date</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in Control and Severance Agreement&#8212;Jon Serbousek</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective Date:&nbsp;&nbsp;November 1, 2019<font style="margin-left:36pt;">Page </font>24</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; </p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>ofix-ex991_7.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
ofix-ex991_7.htm
</title>
</head>
<!-- NG Converter v5.0.19273.161 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Exhibit 99.1</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:565.05pt;;">
<tr>
<td style="width:205.8pt;"></td>
<td style="width:132.15pt;"></td>
<td style="width:132.15pt;"></td>
<td style="width:94.95pt;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="ga0utrbibfaq000001.jpg" title="" alt="" style="width:258px;height:40px;"></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Orthofix Appoints Jon Serbousek as President and Chief Executive Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Arial;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Serbousek succeeds former President and CEO Brad Mason who previously announced his retirement</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LEWISVILLE, TEXAS &#8211; November 1, 2019 &#8211; Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company focused on musculoskeletal products and therapies, announced today the appointment of Jon Serbousek as President and Chief Executive Officer (CEO), effective immediately. He will also serve on the Company&#8217;s Board of Directors. Serbousek succeeds former President and CEO Brad Mason who had previously announced his plans to retire. Mason has resigned from the Company&#8217;s Board of Directors, but will continue to be a consultant for Orthofix for the next 12 months to work with Serbousek to ensure a seamless transition and provide other assistance as needed.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;We are grateful for Brad&#8217;s many contributions to Orthofix. Under his leadership a strong foundation was built that will serve Orthofix well in the years ahead,&#8221; said Ron Matricaria, Orthofix Chairman of the Board of Directors. &#8220;As we move into this next chapter, we are pleased to welcome Jon as President, CEO and Director. I am confident in Jon&#8217;s ability to deliver against our strategic business priorities. His vast experience in the medical device industry and focus on business growth and value creation will be a benefit to our organization.&#8221;&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;I am appreciative of the opportunity to lead the talented team at Orthofix,&#8221; said Serbousek, whose past executive experience includes leadership roles at Medtronic, Biomet, and DePuy Orthopedics. &#8220;I firmly believe through the work of our dedicated team members around the world, we can deliver new levels of products, services and support for our surgeon customers and their patients.&#8221;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Serbousek&#8217;s experience spans more than 30 years in the medical device and biotech industries. He served in several leadership positions at Biomet Inc., including Worldwide President of Biomet Biologics, Worldwide Group President of Orthopedics, and President of U.S. Orthopedics. Prior to joining Biomet, he held various general management positions within Medtronic Inc., including Worldwide Division President, Spine, and Worldwide Vice President and General Manager of Biologics for their Spine and Biologics business. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, Serbousek spent 13 years with DePuy Orthopedics, a Johnson &amp; Johnson company where he served in numerous roles of increasing responsibility, including Vice President of Marketing and Product Development and Vice President of Spinal Operations. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Serbousek has held numerous board positions at for-profit and not-for-profit organizations. He earned his BS in Engineering from Washington State University, his MS in Bioengineering from the University of Utah, and later completed several advanced management programs including a program at the IMD International School of Management in Lausanne, Switzerland. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">About Orthofix</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Orthofix Medical Inc.&#160;is a global medical device company focused on musculoskeletal products and therapies. The Company&#8217;s mission is to improve patients' lives by providing superior reconstruction and regenerative musculoskeletal solutions to physicians worldwide. Headquartered in&#160;Lewisville,&#160;Texas, Orthofix&#8217;s spine and orthopedic extremities products are distributed in more than 70 countries via the Company's sales representatives and distributors. For more information, please visit&#160;<font style="text-decoration:underline;color:#000000;">www.orthofix.com.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Forward Looking Statements </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>This communication contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (&#8220;the Exchange Act&#8221;), and Section 27A of the Securities Act of 1933, as amended, relating to our business and financial outlook, which are based on our current beliefs, assumptions, expectations, estimates, forecasts and projections. In some cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;projects,&#8221; &#8220;intends,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; or &#8220;continue&#8221; or other comparable terminology. These forward-looking statements are not guarantees of our future performance and involve risks, uncertainties, estimates and assumptions that are difficult to predict. Therefore, our actual outcomes and results may differ materially from those expressed in these forward-looking statements. You should not place undue reliance on any of these forward-looking statements. Further, any forward-looking statement speaks only as of the date hereof, unless it is specifically otherwise stated to be made as of a different date. We undertake no obligation to further update any such </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="ga0utrbibfaq000002.jpg" title="" alt="" style="width:258px;height:40px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">statement, or the risk factors described i</font><font style="color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n Part I, Item 1A under the heading Risk Factors in our Form 10-K for the year ended December 31, 2018, to reflect new information, the occurrence of future events or circumstances or otherwise.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:545.4pt;;">
<tr>
<td style="width:205.8pt;"></td>
<td style="width:132.15pt;"></td>
<td style="width:94.95pt;"></td>
<td style="width:27.45pt;"></td>
<td style="width:85.05pt;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONTACT:</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; Mark Quick</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denise Landry</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; Investor Relations</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Media Relations</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; Tel&nbsp;&nbsp;&nbsp;&nbsp;214 937 2924</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tel&nbsp;&nbsp; 214 937 2529</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; <font style="text-decoration:underline;">markquick@orthofix.com</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">deniselandry@orthofix.com</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>ga0utrbibfaq000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ga0utrbibfaq000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  I 0,# 2(  A$! Q$!_\0
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00 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ga0utrbibfaq000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ga0utrbibfaq000002.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[@ .061O8F4 9      !_^$+C$5X:68
M $U- "H    (  <!$@ #     0 !   !&@ %     0   &(!&P %     0
M &H!*  #     0 "   !,0 "    '@   '(!,@ "    %    )"':0 $
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M2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0
M245#('-21T(               $  /;6  $     TRU(4" @
M                                                   18W!R=
M 5     S9&5S8P   80   !L=W1P=    ?     48FMP=    @0    4<EA9
M6@   A@    49UA96@   BP    48EA96@   D     49&UN9    E0   !P
M9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0   _@
M   4;65A<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U120P
M!#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@
M2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@245#
M-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M                                                         %A9
M6B        #S40 !     1;,6%E:(                     !865H@
M    ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(        "2@
M   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                        9&5S8P         N245#
M(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M           N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A
M8V4@+2!S4D="                             &1E<V,         +%)E
M9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M         "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y
M-C8M,BXQ                                  !V:65W       3I/X
M%%\N !#/%  #[<P !!,+  -<G@    %865H@      !,"58 4    %<?YVUE
M87,          0                        */     G-I9R      0U)4
M(&-U<G8        $      4 "@ / !0 &0 > ", *  M #( -P [ $  10!*
M $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L D "5 )H GP"D *D K@"R +<
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MCPFD";H)SPGE"?L*$0HG"CT*5 IJ"H$*F JN"L4*W KS"PL+(@LY"U$+:0N
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M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#_\  $0@
M8P)Y P$1  (1 0,1 ?_$ !\  0 # 0$! 0$  P         )"@L(!@<%! $"
M __$ % 0   & @$" P(("@0,! <   $" P0%!@ '"!()$1,*%!4A%K=8>-@Y
M&B(C%U=WEQ@XJ+@QE-;703)")+56MC>(Z!EI43/5F&%2-$0F)Z?_Q  = 0$!
M  (# 0$!            " <)! 4& P$"_\0 /!$  @$# @0% @,%!@<!
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MS3/W\XYR1@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M:_[IT:=4TFFCUV<,YHP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M6L5K?FS=T 6=I>\JQJ+4S1D)&ZH)HN 3N>_:C(^2_(/F)![/Y@$#\:5,WX.
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M12(F55M(+-P47( J !512 X\D/6F=JMF]<-6VD^><L@@H)$Y&/U3H5-D\*
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M1TQOQN+5.7N5400ND>U\LB43L&NKKUV\QZ;8BJJC5F6RQCE5F53I4.P504$
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M-\Q@VV]Y8KB9WOIINX,W:(S%AE&Z:TEN6DQQ@,J_2?%<6=--0ZK=X[\E&-5
MTJZ7<ZEL>GU78-!LD+<:->*[#6ZG6VN2+:7K]GJ]BCF\O S\'*LE%FDC$R\8
M[2<-UTC&3524*8HB X!XG?6]=5\9--;)Y ;OMT?1-4:EJ<I<[Q:9+S3HQL-%
M)=9DVK1N15[*S$DY.FT8,&R:KR0?+HMFZ:BZJ9# 97_=C]31S;Y\7"W4/0-W
MN7%#B3[<^C*[1->S!JSM#8$ DX42:S.W=B5]P6P>U33/Q,YK\2^0@D4E?9EP
MD3)@[4 K3K+*N%55UU5%UUU#K+++',HJLJH83J*JJ'$QU%%#F$3&$1$1'Q'
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M'L;?DM <7Z)-MG MGD0[VHQGG=UD(]8A!72EF^IJM8A9+)'25:N_*7(<#)
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M8)Y]I/V.CZZHCJ)9C5+G78[W.A':W:K)]:!EO.75\3B7H*4"3?[[1SZ^:CQ
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MU9)KHMI39W%I>:KAUC"4SY_KK95.6?1#;\+P.Z5AK4X>=/3_ .2Q4'Q#I\#
M:9. , 8 P"C=ZWO:$5'<<^#&ES+MS3EQW7LW:";8"];M&*UK18RJ+KG.5T7V
M9NX>;73*4#HG\\R1N@Y/).4X&<Q@%B#TJ]7EI_OB\2):.2*HSH]=Y(6B>.8%
MA%")=\:-M4M%4GE(JD PSMO9$_&&3)X''P,)^DA@/.^J.^W7YS?\,W\GG'W
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M>X;GM$3[2"9#L8>1K$!#MG[<JI57!I5IYA#-UTS@0!^J.^W7YS?\,W\GG'W
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M[0]2;2,E([;UA3H@K9/9]?3\QX_G]S5=FS!2:()#.[2R,JZ\PTDV*E) 9Y.
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M(H^T*TPL.R]!.X!]/T"SQ=KAF<XUC>,L3(N8=S(Q*9'*;=TV6.B8P$53,('
M"UK@# (V.87: [;//)R^F>3G$G5]UNL@GT.-GP#22UKM=8Y!,=JH^V7K61J=
MRFTV*QA42;R#QVT\3&*9$Q#J%,! /MST5O;RM3IR_P!0<A^5.HU7*RRH1,U*
M:WV?66!#E'R&\8U=T>J6<J*)Q 1%U,/%#E#PZ@'\+ .-);T-$.L^44@NYM)1
MT:)4P1:2W#MK-/B'!,H+&4D&?)^ 05*=7Q$H U()"B ")A#J$#^5IZ&5J1TV
M.^[GSARQ(X1,\;M.&";)TNU*H47"+9XMRM?HM'"J("4BIT%RIF$#"F< Z1 Z
MCU7Z);A+!.6[C<O+GDWLDB"B2IV5!B-8ZF9O!3<KJBW=C,U[;#\&:[84DE 0
M706_!4,14@G("0$XO$GL$=IOA@_CK'JGB)1;/?8PS==ML?=B\INVVMI%KX^1
M+PP;&>3M;I\LF!O@7@XZ+-_A_I^' )C, 8!7!YZ^E_X"]Q+ECM;F+NO;O+^K
M[-W!\1OC+!:MOVEX2B,?R?ZVIVK8;W%&6S0%VL#;VFOTEHLZ]HE'76\45.3R
MTS$23 Y ^Y4]K+\_G/\ _6GQU^JK@%B;M[\#]0]MCBW2N)&C+'LBUZXHDQ<Y
MN(F]L2]8G;NY=7FU2MOEDY*2I]/HD"LW;R4NH1N"4:B8B!2E.90X"<P':^ ,
M 8 P!@$$/= ]/3PO[LN_:AR+Y%[.Y/TN[4O3\!I2+B]*735-<JKBJURZ; O3
M&0D&-ZTKL>75L"LOL=\FJJF^2;&;)(%*@4Y5%%0(X/N5/:R_/YS_ /UI\=?J
MJX!,-VZ.S1Q\[7.D-^Z0XL[GY,,VW(&0)-2VQ;S8]/678U GVU7=5:-GM=+-
M-)0M(:R$2@Y]J0+,P<VV%VF05$E$NI(P$2]I]&EVU[Q9K!<[GR<[C-LM]LFI
M.QVBT6/<V@9JP6*P33Q:1F)R<F)'BXX?RDM*/W"B[APNH=594YC&,)A$< _!
M^Y4]K+\_G/\ _6GQU^JK@$_G;C[9_%KM;:(_(+Q@KTT6/DIIY8[QLB^.8*:V
MQL^>7<.S,)&_V> KM5C9(M=C70,(QJTCV3%DT((IH@NLY67 D!P!@'XMDKE?
MN-=GJC;8.)LU5M4+*5RS5N>CVLM!6"OSC%>,F8.:BGR2[*3B9:.=*(.6ZQ#I
M+(J&(<HE$0P"J!<?1D=J6U6VSV>-VCS;HD?8K!,3;&DT[:>E/BE4&DK(.'S>
MLU@+7QTM5G"OP:2X-F82$G(/0;ID\YRLIU*& \W]RI[67Y_.?_ZT^.OU5< G
M0[97;!UCVKM4631FD-]\G=J:CF)X;-7J+R%MVL;A$ZTF'BCM>QK:X6HVH=:R
M<&QM[MR5S(L5W#Q@+Q(7*"*#AP\5<@26X P#_]&_Q@$9?= [==1[@.DAA6HQ
MM>WE0$Y"6T[>G@&1;H/W*1!D:99UT&[ERI3K2+9(%C$(=5DZ21<I@8"*HKY3
M[4]R\SMSKOOSZKN@9+4<FTN+:7*[!-I>Y;JZ5:4HN4'2JE'$W=WM?A=R]O\
MV\.BUN'&4I8UY\$F_P!JU<:3?M7**M$W"2C-5HXRSW]I:MV!I38%JU9M.JRM
M*OU*E5H:R5N91!)XP>) 50AR'3,HV>L'K90B[5T@=5L[;*IK(J'2.0X['M)U
M;3M=T[$U?2,N%_3K\%*$XO@U_P!4TZJ46E*,DXR2::-9FL:/J>@:GF:/K&'/
M'U+'FXSA)4::_P"3BU1QDFXRBU*+::9X#.Q.M/056IVF]6*'J%)K<[;[98'J
M<=!5FLQ+^=GYE^J!A391<1&(.G[]T<"B($23,;P 1\/ !SC9>9B:?C7LW/RK
M=G#MQZISG)0A%><I2:27JV<G#PLS4<JQ@Z?BW+^;=ETPMVXN<Y-^$8Q3;?HD
M6.N$?IV]K;&]TWOF38G&FZ:KY;M+5-4<QTIM:80'I.FG/3 IR57HC=PF8IA(
M4)21\ ,DJ@S4\#!,N^_DII&F>]I^R<99V:N'W%Q2CCQ?Z(_3<NM>?\N')J4U
MP*E[?_&#6=4]C4=]93P,!\?M[;C+(DOUR^JW93\OYD^:<8/B6M^.W%?C_P 4
M::E1=!:PK.O(84T"R;R,:>T62RN&Y3%3?VRU/C.K#9WY>LW2H]<K"D4>A,")
M@4@2'N7=NX]WYSU#<6JW<F_5]*DZ0@GX6[:I"VO2,57FZOB65M?9VVMFX"T[
M;>D6L6Q1=3BJSN-?VKEQUG<EZSDZ<E1413"]0+R9;;NYK?DMK\C[;4.-=8+0
M!!(PG:'V+..$Y[8CIN(E*8JS,P1L.X+X> .(<_@(@(#EP?'/:TM!V+_5LFUT
MYNJ7?>]?9@NBRG^/UW%^FXB#_DMNR&X-_?T?&N]6#I-GV?3WYOKOM>J^BU+]
M5ID)U2I]LOUBBJA1JQ8+E;)UT5E"UFK0\A/S\L\. B5M&Q$4W=/WJX@ CTII
MF'P 1_H#,ZYF;AZ=C7LW4,NW8P[:K*=R2A"*\Y2DTDOQ9@'"P<W4LJS@Z=B7
M;^;<=(6[<93G)^48Q3;?X(LF\(_3J[&O'NF]\T[*XU76%/+>):?I#^+D]D2B
M/X*B*5GM!"RU9IS=<O@*C=J62?BF8R9Q9+AXEF#??R6TS ][3]C8JR\M</N;
MJE&S%^/1;^F=QKP<NB%>*]R/.J^W_P 7M4U#V=1W[EO#Q'Q^VM.,K\EX>Y<^
MJW:3\8Q]R=*I^W+E;DU;JW7^E-?U75FK*K%4J@TJ*1AJW6X9$4F;!FD)E#G.
M=0RCEZ_>N5#KNG2YU7+MRJHLLH=4YSC&^K:MJ.NZCEZOJ^7._J-^;E.<GQ;_
M .B25%&*2C&*48I))%KZ/H^F:!IF'H^CX<,?3<>"C"$51)+_ )N3=7*3;E*3
M<I-MMGO\ZX[(8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MQC!'7V>,/;C & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8!__]._Q@# & , 8 P"(IY[J_ZG</Y_[/\ \</B/_G_
M .TW\<_VF_BW\8;/\6_V-_=O_P"B_P DWLO_ )_NW_\ +/;?;/?O^<>&9EA[
MW_Y5>Z?ZC]E]QP^Q]K['KZ+?7_4NK_5_<5Y=?^GZ>C[?Z3"4_9__ %RQU?TS
M[[[?C]_[OW_M]=SV_P"F=/\ I/MJ<_;_ -1U^Y]S]1+KF&C-HP!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
#!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>ofix-20191031.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2019-10-29T21:13:11.4219389+00:00 -->
<!-- Version            : 5.0.0.208 -->
<!-- Package ID         : bf853a59a24d42f38fbab94c72f2ed83 -->
<!-- Copyright (c) 2019 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:ofix="http://www.orthofix.com/20191031" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.orthofix.com/20191031" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" namespace="http://xbrl.sec.gov/country/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2019-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2019-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2019-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" namespace="http://xbrl.sec.gov/invest/2013-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2011-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" namespace="http://fasb.org/srt/2019-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd" namespace="http://fasb.org/srt-roles/2019-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" namespace="http://fasb.org/srt-types/2019-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2018-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" namespace="http://fasb.org/us-gaap/2019-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd" namespace="http://fasb.org/us-roles/2019-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" namespace="http://fasb.org/us-types/2019-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.orthofix.com/20191031/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ofix-20191031_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ofix-20191031_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.orthofix.com/20191031/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>ofix-20191031_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2019-10-29T21:13:11.4219389+00:00 -->
<!-- Version            : 5.0.0.208 -->
<!-- Package ID         : bf853a59a24d42f38fbab94c72f2ed83 -->
<!-- Copyright (c) 2019 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of each class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Name of each exchange on which registered</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>ofix-20191031_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2019-10-29T21:13:11.4219389+00:00 -->
<!-- Version            : 5.0.0.208 -->
<!-- Package ID         : bf853a59a24d42f38fbab94c72f2ed83 -->
<!-- Copyright (c) 2019 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.orthofix.com/20191031/role/TemplateLink" xlink:href="ofix-20191031.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.orthofix.com/20191031/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="ofix-20191031.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orthofix.com/20191031/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M?_A=A%TP=F?_L?%94';PZR[D%U!+ P04    " #\@6%/F5R<(Q &  "<)P
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M)J$)<IQHNS"BL2P$$8WR1BUX:S2?-:PS%L/35B#E2SC"K\T5]]B0F/.Q#L=
M@HK5]*M>S'A<T0G\1[;(?:"]OXF66'$Q^&'PJ]&S_VTP",\.&C'._MAL]3T[
MMU9.[Z5HM8*XEM\63&XL6&1\K4,ZX\2KYPLWI?( .$HNX%!41^2[X_8,(ZZW
M:6QNU9S^AYK_]CZWH,%Q>13MK_Z_O,M_HI@MW7-HT:L&W5!2#D*BT(O&3M0U
M1'GAA<SIE_#PRJL^V?O4TR,O_0-^Q>_GUM#P0>)S6/$<S.EN?PHO3?*P99TW
MBISN]F>HQ:#>S@7WOT3Q U!+ P04    " #\@6%/,/_D<D0!   \ @  #P
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MD72FUS>36PZ[U_J!L7?[ZE32CQKCQ]W] %!+ P04    " #\@6%/_\ F"+T
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M.N_6_VATF<N@7?S-R$=*[4%?#?_)\@M02P$"% ,4    " #\@6%/'R// \
M   3 @  "P              @ $     7W)E;',O+G)E;'-02P$"% ,4
M" #\@6%/)^B'#H(   "Q    $               @ 'I    9&]C4')O<',O
M87!P+GAM;%!+ 0(4 Q0    ( /R!84^+EKI<[@   "L"   1
M  "  9D!  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( /R!84^97)PC
M$ 8  )PG   3              "  ;8"  !X;"]T:&5M92]T:&5M93$N>&UL
M4$L! A0#%     @ _(%A3X4T_'"A @  DPL  !@              ( !]P@
M 'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( /R!84]&?>*2
M9P(   X&   4              "  <X+  !X;"]S:&%R9613=')I;F=S+GAM
M;%!+ 0(4 Q0    ( /R!84^ZH3F*UP$  #(&   -              "  6<.
M  !X;"]S='EL97,N>&UL4$L! A0#%     @ _(%A3S#_Y')$ 0  / (   \
M             ( !:1   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( /R!
M84__P"8(O0   (4"   :              "  =H1  !X;"]?<F5L<R]W;W)K
M8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( /R!84\+C]@#(0$  %<$   3
M          "  <\2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     *  H
*@ (  "$4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>97</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ofix-8k_20191031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orthofix.com/20191031/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="ofix-8k_20191031.htm">ofix-8k_20191031.htm</File>
    <File>ofix-20191031.xsd</File>
    <File>ofix-20191031_lab.xml</File>
    <File>ofix-20191031_pre.xml</File>
    <File>ofix-ex101_34.htm</File>
    <File>ofix-ex102_35.htm</File>
    <File>ofix-ex991_7.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ofix-8k_20191031.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "ofix-8k_20191031.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ofix-20191031_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ofix-20191031_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "ofix-20191031.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd",
      "https://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 97,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "ofix",
   "nsuri": "http://www.orthofix.com/20191031",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "ofix-8k_20191031.htm",
      "contextRef": "C_0000884624_20191031_20191031",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document And Entity Information",
     "role": "http://www.orthofix.com/20191031/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "ofix-8k_20191031.htm",
      "contextRef": "C_0000884624_20191031_20191031",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.orthofix.com/20191031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.orthofix.com/20191031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.orthofix.com/20191031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.orthofix.com/20191031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.orthofix.com/20191031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.orthofix.com/20191031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.orthofix.com/20191031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.orthofix.com/20191031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.orthofix.com/20191031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.orthofix.com/20191031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.orthofix.com/20191031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.orthofix.com/20191031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.orthofix.com/20191031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.orthofix.com/20191031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.orthofix.com/20191031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.orthofix.com/20191031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.orthofix.com/20191031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of each class"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.orthofix.com/20191031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Name of each exchange on which registered"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.orthofix.com/20191031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.orthofix.com/20191031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.orthofix.com/20191031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.orthofix.com/20191031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6612102384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Oct. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct. 31,  2019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ORTHOFIX MEDICAL INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000884624<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-19961<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1340767<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3451 Plano Parkway<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Lewisville<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">75056<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">214<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">937-2000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of each class</a></td>
<td class="text">Common stock, $0.10 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">OFIX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Name of each exchange on which registered</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>ofix-8k_20191031_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ofix-20191031.xsd" xlink:type="simple"/>
    <context id="C_0000884624_20191031_20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000884624</identifier>
        </entity>
        <period>
            <startDate>2019-10-31</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="C_0000884624_20191031_20191031" id="F_000001">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="C_0000884624_20191031_20191031" id="F_000004">0000884624</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="C_0000884624_20191031_20191031" id="F_000000">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="C_0000884624_20191031_20191031" id="F_000002">2019-10-31</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="C_0000884624_20191031_20191031" id="F_000003">ORTHOFIX MEDICAL INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0000884624_20191031_20191031" id="F_000007">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="C_0000884624_20191031_20191031" id="F_000006">0-19961</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="C_0000884624_20191031_20191031" id="F_000008">98-1340767</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="C_0000884624_20191031_20191031" id="F_000009">3451 Plano Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="C_0000884624_20191031_20191031" id="F_000010">Lewisville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="C_0000884624_20191031_20191031" id="F_000011">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="C_0000884624_20191031_20191031" id="F_000012">75056</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="C_0000884624_20191031_20191031" id="F_000013">214</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_0000884624_20191031_20191031" id="F_000014">937-2000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="C_0000884624_20191031_20191031" id="F_000015">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="C_0000884624_20191031_20191031" id="F_000016">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="C_0000884624_20191031_20191031" id="F_000017">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="C_0000884624_20191031_20191031" id="F_000018">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="C_0000884624_20191031_20191031" id="F_000005">false</dei:EntityEmergingGrowthCompany>
    <dei:Security12bTitle contextRef="C_0000884624_20191031_20191031" id="F_000019">Common stock, $0.10 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="C_0000884624_20191031_20191031" id="F_000020">OFIX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="C_0000884624_20191031_20191031" id="F_000021">NASDAQ</dei:SecurityExchangeName>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001564590-19-039426-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-19-039426-xbrl.zip
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M08Q_?(/JA6:Y6E@C*JFFI\DY]'KA3^1P496W?.C[[E?HZUCFG:I05],I2J@
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MG%OGA!7HTKZ83:/;*^:?V4CYX1]02P,$%     @ _(%A3P."559"'@  1.$
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M9 Q2>R8TH$S@@.ZH91KVP%PF@/EW;='C?B?Q=Q.3M14P*!.C;YRZ ]G0"Q6
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M+&FXO%S.MQ>5Y, P9O=%H]0VG&<-SM-4QUK@/&WVG=7JL\OXCNX33JG?4P3
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M^C%%I B;W:U*@L[W4=@''O_>=(5=T%VWB6^1TZB@E T<39(H]$-3.!!HHSL
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M=Q$W<YI2X8-KV0QSS@'P/Y0HI#;KZ&^YRC-\V08M%O1B&RMR+R;I@!\XI<L
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M\2..VRQ$G0OWKHA9'01@I=B1BU3_,7?Y@R U;D63_?:Y^[[;L^#8OX!$&Q-
M6 -$;3M_7NLFK25R/3%4TC+&U(!45QK5_@*4;5W8T3T6X'$ 1]4, JS85 #V
M&8BC#XRM3F1K4SCMLVPBYF6J,BK!0\HV*]\=[@99:-ME[(MBOUIH@#F+S9]Q
MQLH SS74/9O F0ZI<L>SJQ;9G.\?&M7!\SW?[L&N$8J("DX(24QH+HMJYN:
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MX*.3?BIYRQ;ECC/;WV J>=L6Z/8SV]]4*GG+EN/K9;;Q)/M&LMNK VZFH?K
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MQ@2_D=E +Z!QT,SHT;O8T&KCW.[Q0T[N@I:]RP(34NH@@T$UP(O$M&'X1U6
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MS,:!I7Y9A5<B-TE*"=@>O*DIX$%%?:L@C;]T.-)TP%*XR7)NV7)\J71%RWE
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M"L.-=Y%&;F/NR,T[#99E=<G0ZJ]!Y[4%I\;&0=0P9B-]/S \<5$:N/S45(J
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MT+5.9<Q[".,P=2SQ+-L?#WIG:8(^G7/?6J7NK(?<_?MMF[-R?(@W0NA7Q<W
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M 1PB?:%_>J#=,\"-]0<LQ<+8T313^AR;V;C!/H8%]M&THQ$\383!W+I"<4*
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M+GAS9%!+ 0(4 Q0    ( /R!84^@R.HC( <  )=)   5              "
M ?X$  !O9FEX+3(P,3DQ,#,Q7VQA8BYX;6Q02P$"% ,4    " #\@6%/(DDM
M9?<$  #<*P  %0              @ %1#   ;V9I>"TR,#$Y,3 S,5]P<F4N
M>&UL4$L! A0#%     @ _(%A3P."559"'@  1.$  !0              ( !
M>Q$  &]F:7@M.&M?,C Q.3$P,S$N:'1M4$L! A0#%     @ _(%A3^XQN5*6
M*P  KE$! !$              ( ![R\  &]F:7@M97@Q,#%?,S0N:'1M4$L!
M A0#%     @ _(%A3UX>+)$J90  ML8" !$              ( !M%L  &]F
M:7@M97@Q,#)?,S4N:'1M4$L! A0#%     @ _(%A3T!+5AOH#   X4(  !
M             ( !#<$  &]F:7@M97@Y.3%?-RYH=&U02P4&      < !P##
) 0  (\X

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
